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Background and aim of the work 1 
B. Introduction 
1 Background and aim of the work 
Cardiovascular disease is currently the leading cause of death in the developed 
countries, and atherosclerosis is by far the most prominent contributor (Murray 
and Lopez, 1997; Libby, 2002). Considerable effort is therefore made to 
develop new therapeutic strategies to combat and reduce cardiovascular 
complications. One possibility is to investigate natural products, especially those 
that are, thanks to epidemiological studies or their use in folk medicine, already 
discussed to have potentially beneficial effects in this field.  
In this regard, the polyphenolic stilbene-derivate trans-resveratrol (trans-3,5,4`-
trihydroxystilbene) was a good candidate. As a major constituent of red wine, 
this substance has been proposed to partially account for the beneficial effects 
attributed to this beverage in cardiovascular disease (Wu et al., 2001; Soleas et 
al., 2001). 
Vascular smooth muscle cells (VSMCs) are the prime cellular component of the 
normal artery as well as of intimal lesions that develop in response to arterial 
injury. Consequently, hypertrophy and hyperplasia of VSMCs are hallmarks of 
vascular disorders such as atherosclerosis and restenosis (Touyz and Schiffrin, 
2000; Lusis, 2000; Dzau et al., 2002).  
The purpose of this study was therefore to investigate the effects of resveratrol 
on VSMC hypertrophy and hyperplasia. To achieve this aim we employed 
primary rat aortic smooth muscle cells, as these are widely used and accepted 
in cardiovascular research. Angiotensin II (Ang II), the main effector peptide of 
the renin-angiotensin system, was applied to induce VSMC hypertrophy, while 
calf serum, a classical mitogenic stimulus, was used for induction of cellular 
proliferation.  
In particular, the following questions were addressed: 
1. Is resveratrol able to attenuate VSMC hypertrophy induced by Ang II- 
treatment, and what are the mechanisms underlying a putative effect? 
2. What signalling pathways are involved in mediating the antiproliferative 
properties exerted by resveratrol in calf serum-treated VSMCs? 
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2 Vascular Smooth Muscle Cells 
2.1 VSMCs in neointima formation and atherosclerosis 
In intact arteries, VSMCs are normally in a quiescent, non-proliferative state. 
However, upon stimulation by mechanical injury or growth factors, VSMCs enter 
the cell cycle and start to replicate. After carotid injury, VSMC proliferation 
begins within hours, and by day 4 cells start to migrate to the intima, where 
proliferation continues for approximately 2 weeks. Finally, extracellular matrix 
(ECM) synthesis starts and additionally increases intimal volume (Braun-
Dullaeus et al., 1998). At first, thickening of the atherial wall is compensated by 
gradual dilation, a process referred to as vascular remodelling, but continuous 
increase in intimal mass finally hampers blood flow and results in clinical 
manifestation (Libby, 2002; Ross, 1999).  
2.2 VSMCs in culture 
Although cultured VSMCs retain many characteristics of their in vivo 
counterparts, culturing leads to changes in expression of some smooth muscle 
specific proteins and properties, for example loss of the cyclic GMP-dependent 
kinase (PKG) (Lincoln et al., 2001; Brophy et al., 2002). Concomitantly, VSMCs 
adopt a non-contractile, more synthetic phenotype characterised by enhanced 
proliferation and extracellular matrix deposition that resembles intimal VSMCs 
(Shanahan and Weissberg, 1998). Therefore, subcultured VSMCs are a 
suitable model for cells found in the neointima of atherosclerotic leasons.  
3 Resveratrol 
3.1 Occurrence and history  
Resveratrol (trans-3,5,4´-trihydroxystilbene) is found in a narrow range of 
spermatophytes, including grapes, peanuts and mulberries. It was first isolated 
1963 from the roots of the weed Polygonum cuspidatum that has a long 
tradition in Chinese and Japanese folk-medicine, but major interest has not 
been focused on this compound until its discovery in red wine 1992 (Soleas et 
al., 1997). The highest concentrations of resveratrol are found in grape skin (50-
100 µg/g), and due to its physiological role as a phytoalexin it is more abundant 
in grapes grown in cooler climates where fungal infections are more common.  
3.2 Biosynthesis and biological function 
Resveratrol is synthesised from phenylalanine in several steps (Fig. 1). 
Phenylalanine derived from the Shikimate pathway is converted to cinnamic 
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acid through oxidative deamination by the action of phenylalanine ammonia 
lyase. Cinnamic acid is enzymatically hydroxylated to p-coumaric acid, which is 
subsequently converted to the CoA ester derivate by a specific CoA ligase. 
Condensation of 4-coumaroyl CoA with three malonyl CoA units by the enzyme 
resveratrol synthase, a stilbene synthase, results in the formation of resveratrol 
(Wu et al., 2001). 
The main task of resveratrol and its condensation products, a family of polymers 
given the name viniferin, in the plant cell is to function as a phytoalexin. 
Consequently, amounts are greatly increased upon fungal infection especially in 
the skin, and barely detectable in the flesh of healthy grapes. These findings 
implicate that resveratrol synthase is not expressed constitutively but induced 
upon UV-irradiation, trauma and infection. In contrast, chalcone synthase, a 
constitutively active enzyme, is able to catalyse the generation of a chalcone 
from p-coumaroyl CoA and three malonyl CoA in a pathway alternative to 
stilbene synthesis. Chalcones are then further converted to flavonoids (Soleas 
et al., 2001). 
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Fig. 1. Biosynthesis of resveratrol 
3.3 Properties 
Since its discovery in red wine 1992 (Siemann EH and Creasy LL, 1992), a 
plethora of studies have been performed, generating a vast and still increasing 
number of biological properties attributed to resveratrol. In addition, many of 
these effects seem to be tissue- as well as cell type specific (for review, see 
(Wu et al., 2001; Soleas et al., 2001; Gusman et al., 2001). For that reason, this 
paragraph will focus on distinct features of major interest for this substance. 
3.3.1 Antioxidant activity 
Resveratrol has proved to be a potent antioxidant in many biological systems 
(Soleas et al., 2001). Its antioxidant properties have been demonstrated for the 
first time by Frankel et al. (Frankel et al., 1993), revealing that resveratrol was 
more potent than α-tocopherol but less potent than quercetin in inhibiting 
copper-catalysed oxidation of human low density lipoprotein (LDL) in vitro. 
Resveratrol 5 
3.3.2 Oestrogenic activity 
Resveratrol has structural similarities with diethylstilbestrol, a synthetic 
oestrogen, and Gehm et al. were the first to describe binding of resveratrol to 
the oestrogen receptor and transcription of oestrogen-responsive reporter 
genes transfected into human breast cancer cells. However, the extent of these 
effects was different according to the cell type investigated (Gehm et al., 1997), 
and so far, in vivo studies have failed to show oestrogenic activities in whole 
animals (Soleas et al., 2001). 
3.3.3 Chemopreventive  and anti-inflammatory activity 
Resveratrol has been demonstrated to interfere with cyclooxygenases (COX), 
but alterations of COX gene expression and activity by resveratrol are variable 
in different experimental models (Jang et al., 1997; Subbaramaiah et al., 1998). 
However, anti-inflammatory properties of resveratrol were confirmed in vivo, as 
resveratrol strongly suppressed carrageenan-induced paw oedema in both the 
acute and the chronic phase (Jang et al., 1997). In addition to interference with 
COX, inhibition of the 5-lipoxygenase and the 15-lipoxygenase pathway was 
demonstrated in several models (Soleas et al., 2001). 
Most studies agree that resveratrol is able to induce apoptosis in many cancer 
cell lines via p53-dependent as well as p53-independent pathways (Lin et al., 
2002; She et al., 2001; Tinhofer et al., 2001; Mahyar-Roemer et al., 2001). 
Nevertheless, one report describes inhibition of hydrogen peroxide-induced 
apoptosis in rat pheochromocytoma (PC12) cells by resveratrol (Jang and Surh, 
2001). 
Furthermore, resveratrol was shown to inhibit activation of two important 
transcription factors, activating protein 1 (AP-1) and nuclear factor κB (NF-κB). 
The former experiments were conducted in PMA- and UV-irradiated Hela cells. 
The authors suggested inhibition of protein kinase C (PKC) and tyrosine 
kinases to be responsible for this effect (Yu et al.,2001). Suppression of NF-κB 
activation has been linked to decreased IκB-degradation that seemed to be, in 
turn, caused through interference with yet unidentified upstream pathways 
(Holmes-McNary and Baldwin, Jr., 2000; Tsai et al., 1999). 
Additionally, in Hep G2 cells, resveratrol inhibits induction of mRNA, protein 
expression and enzyme activity of the cytochrome P450-dependent enzyme 
CYP1A1 that is involved in dioxin metabolism (Ciolino et al., 1998; Casper et 
al., 1999), although, on the other hand, others report induction of CYP1A1 
mRNA by resveratrol in HeLa cells (Frotschl et al., 1998). 
Another aspect of resveratrol`s putative anticarcinogenic activities is its ability to 
induce quinone reductase, a phase II enzyme capable of metabolically 
detoxifying carcinogens (Jang et al., 1997). 
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3.3.4 Influence on cell cycle and proliferation 
Resveratrol exerts antimitogenic properties in a number of cell lines including 
VSMCs, inhibiting proliferation and DNA synthesis in a dose-dependent manner 
(Zou et al., 2000; Zou et al., 1999; Adhami et al., 2001; Sgambato et al., 2001; 
Wolter et al., 2001). In this regard, cell free in vitro experiments revealed that 
resveratrol is an inhibitor of ribonucleotidreductase (Fontecave et al., 1998) as 
well as DNA-polymerase α and δ (Stivala et al., 2001). Depending on the cell 
type investigated, resveratrol showed divergent effects on other important cell 
cycle proteins like the cyclins, the retinoblastoma protein (Rb) or p21Cip1 (Wolter 
et al., 2001; Adhami et al., 2001; Ahmad et al., 2001; Hsieh et al., 1999; Hsieh 
and Wu, 1999; Ragione et al., 1998; Kawada et al., 1998). In VSMCs, however, 
modulation of these proteins by resveratrol has never been investigated.  
3.3.5 Cardiovascular effects 
In addition to antiproliferative and antioxidative effects, prevention of platelet-
aggregation by resveratrol has been described in several studies (Pace-Asciak 
et al., 1995; Pace-Asciak et al., 1996; Bertelli et al., 1995). 
Furthermore, resveratrol has been shown to reduce tumour necrose factor α 
(TNF-α)-induced expression of the adhesion molecules ICAM-1 and VCAM-1 as 
well as adhesion of U937 monocytoid cells to human saphenous vein 
endothelial cells (Ferrero et al., 1998).  
Moreover, Zou et al. provided evidence that resveratrol is capable of reducing 
intimal hyperplasia of the injured vascular wall in a rabbit model (Zou et al., 
2000). 
More recently, Orallo et al. reported that resveratrol increased NO bioavailability 
via inhibition of NADPH oxidase activity in rat aortic homogenates, while eNOS 
activity was not altered under these conditions (Orallo et al., 2002). Regarding 
eNOS activity, similar results were obtained in our group (Leikert et al., 2002), 
but others report an increase in eNOS activity, protein and mRNA by resveratrol 
(Wallerath et al., 2002). 
3.3.6 Bioavailability  
Recent attention has been drawn to bioavailability of resveratrol, allowing better 
evaluation of the likeliness of in vivo efficacy. Goldberg et al. reported that 
Resveratrol was readily absorbed with an assumed bioavailability around 90%; 
however, clearance from the blood stream was very rapid (Soleas et al., 2001). 
On the other hand, Bertelli et al. suggested an accumulation of resveratrol in 
different organs after prolonged administration to rats (Bertelli et al., 1996), 
while Kuhnle et al. investigated absorption and metabolism of resveratrol in an 
isolated small intestine model and found that the majority of resveratrol was 
absorbed as a glucuronide conjugate (Kuhnle et al., 2000). This has been 
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confirmed by a recent study showing that trans-resveratrol-3-O-glucuronide and 
trans-resveratrol-3-sulfate were the prime metabolites found in rat urine and 
mouse serum (Yu et al., 2002). 
So far, too little is known for judging the amounts of resveratrol needed in 
humans to obtain – potentially - beneficial effects. However, evaluating the 
existing data on resveratrol`s bioavailability, it seems unlikely that biologically 
active amounts of resveratrol can be reached exclusively by means of ingestion 
of resveratrol-containing foods.  
4 Angiotensin II 
4.1 History 
Synthesis and pharmacology of Ang II were first described more than 50 years 
ago. Since then, Ang II was seen primarily as a potent and important 
vasoconstrictor. It was not until the beginning of the 1990s that Ang II was 
implicated in vascular pro-inflammatory and proliferative actions. Subsequently, 
however, rapid progress was made in understanding the mechanistic 
background of these findings (Alexander and Dzau, 2000). 
4.2 Structure and biosynthesis 
Ang II is an octapeptide hormone that can be produced systemically via the 
circulating (also termed renal) renin-angiotensin system, or locally by means of 
tissue renin-angiotensin systems (Touyz and Schiffrin, 2000).  
In the circulating renin-angiotensin system, renal-derived renin cleaves the 
hepatic-derived α-globulin angiotensinogen at the N-terminus, thus producing 
Ang I, a decapeptide. In the lungs, Ang I is converted into Ang II by the action of 
the dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE).  
This step can be catalysed also by several non-ACEs, such as chymase, 
carboxypeptidase and cathepsin G. However, although for example chymase is 
present in atherosclerotic lesions, Ang II colocalises with ACE rather than with 
chymase, suggesting that Ang II generation in the atherosclerotic vessel 
depends predominantly on ACE (Schmidt-Ott et al., 2000). 
In addition, Ang I can be transformed to the heptapetide Ang II (1-7) by tissue 
endopeptidases. Ang II (1-7) seems to be a naturally occurring antagonist of 
Ang II actions, with vasodepressor as well as antihypertensive properties 
(Touyz and Schiffrin, 2000).  
Degradation of Ang II to Ang III and Ang IV is performed by aminopeptidases 
(Touyz and Schiffrin, 2000). 
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Angiotensinogen
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Angiotensin I
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Angiotensin II
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Angiotensin IVAngiotensin III Angiotensin II (1-7)
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Chymase
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Fig. 2. Pattern of the renin-angiotensin system. Adapted from (Touyz and Schiffrin, 2000). 
In recent years, it has become evident that generation of Ang II is not limited to 
the circulating renin-angiotensin system; instead, all components are expressed 
in the vessel wall (Schmidt-Ott et al., 2000).  
Angiotensinogen-mRNA was found in VSMCs of healthy blood vessels, and 
levels increased in the media as well as in the neointima after aortic balloon 
injury in rats (Rakugi et al., 1993). Renin mRNA and protein were detected 
predominantly in the media and again, elevated levels were observed after 
balloon injury (Iwai et al., 1997). ACE seems to prevail in endothelial cells, but 
in atherosclerotic lesions it can be detected also in macrophages (Fukuhara et 
al., 2000). Interestingly, a recent study showed that in the human forearm in situ 
generated Ang II is more important for vasoconstriction than circulating Ang II 
(Saris et al., 2000).  
Taken together, there is evidence that these tissue renin angiotensin systems 
may play an important role in local regulation of blood flow as well as in the 
pathogenesis of cardiovascular disease (Touyz and Schiffrin, 2000; Weiss et 
al., 2001). 
4.3 Receptors 
Ang II mediates its effects through the action of the G protein-coupled receptors 
(GPCRs) AT1 and AT2. AT3 and AT4 receptors have been identified, but their 
pharmacology is not entirely clear yet (Touyz and Schiffrin, 2000).  
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Most of the vascular effects of Ang II are mediated by the AT1-R, a glycoprotein 
composed of 359 amino acids that activates phospholipase C (PLC) via a 
heterotrimeric Gq protein (Touyz and Schiffrin, 2000).  
In the vessel wall, AT1-R are localised mainly in VSMCs. Levels in the adventitia 
are low, whereas endothelial cells do not seem to contain significant amounts of 
AT1-R (Allen et al., 2000; Zhuo et al., 1998). Of interest, the density of AT1-R is 
increased in the media of diseased blood vessels compared to healthy animals 
(Yang et al., 1998). While, in rodents, two subtypes termed AT1A and AT1B 
sharing 94% sequence homology have been characterised, there is only one 
AT1-R in humans (Allen et al., 2000). 
The AT2-R is, as well, a seven-transmembrane GPCR, but has low sequence 
homology (around 32%) with the AT1-R. It is a 363 amino acid protein 
expressed at high levels in foetal tissues and decreases rapidly after birth 
(Yamada et al., 1999). In healthy blood vessels, only 10% of the total 
angiotensin receptors are of the AT2-type (Schmidt-Ott et al., 2000). AT2 seem 
to be localised predominantly in adventitia and endothelial cells, but not in 
VSMCs (Wang et al., 1998; Zhuo et al., 1998). There is evidence that AT2-R 
levels, in contrast to AT1-R, are not altered in atherosclerosis (Yang et al., 
1998). 
So far, the main function of the AT2-R is believed to lie in functionally 
antagonising the vasoconstrictor actions of the AT1-R. This is achieved by 
inhibition of the proliferative and growth-promoting effects mediated by the 
AT1-R and by inducing apoptosis (Allen et al., 2000). 
4.4 Role in haemodynamics 
Ang II leads to VSMC contraction within seconds. This effect is a consequence 
of PLC activation through the Gq-coupled AT1-R and subsequent increase in 
intracellular Ca2+ levels (Touyz and Schiffrin, 2000). Ca2+ associates with 
Calmodulin, leading to activation of the myosin light chain kinase that is a 
prerequisite for contraction (Morano, 1992). 
Ca2+-increase after Ang II stimulation is biphasic. PLC hydrolyses 
4,5-phosphorylated phosphatidylinositol (PtdIns) to generate inositol 
trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilises intracellular Ca2+ 
from the sarcoplasmatic reticulum, leading to a rapid transient increase in Ca2+ 
levels. The second wave is more sustained and results from transmembrane 
Ca2+ influx. The exact signalling mechanisms triggered by Ang II to induce Ca2+ 
influx are unclear, but direct or indirect activation of different Ca2+ channels 
have been proposed. In addition to IP3-mediated mobilisation of intracellular 
Ca2+ and influx of extracellular Ca2+, tyrosine kinase-dependent increase in 
intracellular Ca2+ has been suggested (Touyz and Schiffrin, 2000). 
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The other second messenger generated by PLC, DAG, also contributes to 
vasoconstriction. DAG, together with Ca2+ and phosphatidylserine, activates 
PKC, a serine/threonine kinase existing in at least 11 isoforms. PKC stimulates 
activation of the Na+/H+ exchanger, leading thus to intracellular alkalinisation. It 
has been demonstrated that activation of the Na+/H+ exchanger and 
alkalinisation induces vasoconstriction by increasing Na+ and Ca2+ and 
sensitising the contractile machinery (Touyz and Schiffrin, 2000). 
Additionally, Ang II regulates blood pressure and plasma volume by stimulation 
of renal Na+ and water resorption, aldosterone release, sympathetic nervous 
activity and thirst responses (Touyz and Schiffrin, 2000).  
4.5 Role in development of cardiovascular disease 
Promotion of cardiovascular disease by Ang II is not limited to VSMCs but 
involves all components of the vessel wall. In this chapter, a short summary of 
Ang II actions in the vascular wall in general will be given first. Subsequenty, the 
role of Ang II in VSMC responses will be discussed more detailed. 
4.5.1 Ang II actions in the vessel wall 
Atherosclerosis is now considered to be a chronic inflammatory disease, 
initiated by accumulation of lipid-laden macrophages and endothelial 
dysfunction (Ross, 1999). Interestingly, Ang II can mimic many features of 
atherosclerosis, and triggers both inflammation and oxidative stress (Weiss et 
al., 2001).  
Ang II is critically involved in generation of reactive oxygen species (ROS) in the 
vessel wall. The most important source of ROS in the vessel is NAD(P)H 
oxidase, an enzyme first discovered in leukocytes but now known to be 
expressed also in vascular cells. Other potential sources of ROS are xanthine 
oxidase, lipoxygenases, cytochrom P450 monooxigenases and myeloperoxidase 
(Griendling et al., 1994; Zhang et al., 1999; Warnholtz et al., 1999; Hayashi et 
al., 2001).  
Enhanced ROS generation provoked by Ang II contributes to endothelial 
dysfunction and oxidation of LDL. Oxidised LDL (oxLDL) favours inflammation 
by activation of vascular cells and acting as a chemoattractant for monocytes 
and T-lymphocytes. In fact, its accumulation in the vessel wall is now 
considered a main trigger for many events seen in early atherosclerosis 
(Steinberg, 2002). Ingestion of oxLDL by tissue macrophages gives rise to foam 
cells, a major constituent of atherosclerotic plaques. Additionally, Ang II 
enhances leukocyte infiltration of the vessel wall by increasing expression of 
cell adhesion molecules on endothelial cells and VSMCs (Schmidt-Ott et al., 
2000).  
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In endothelial cells, Ang II is capable of triggering apoptosis, and this may 
contribute to damage in the endothelial cell monolayer (Schmidt-Ott et al., 
2000). 
4.5.2 Ang II and VSMCs 
Molecular effects  
Ang II actions in VSMCs extend far beyond vasoconstriction. Through the 
AT1-R, Ang II activates a multitude of intracellular pathways that finally lead to 
altered VSMC function as described below. These pathways include 
phosphorylation and activation of various kinases and phospholipases (Touyz 
and Schiffrin, 2000). Pathways and signalling molecules important for this work 
are discussed separately in discrete chapters. 
Long-term effects on VSMC function 
Ang II stimulates protein synthesis and causes cellular hypertrophy in cultured 
VSMCs (Geisterfer et al., 1988; Berk et al., 1989). In the presence of other 
growth factors, however, Ang II is also capable of inducing hyperplasia in 
cultured VSMCs, and long term infusion of Ang II in normal and carotid balloon 
injured rats augmented VSMC proliferation (Daemen et al., 1991). Additionally, 
Ang II has been shown to activate VSMC migration in transwell-culture 
chambers (Xi et al., 1999). 
In addition to these direct responses, Ang II induces production of various 
growth factors, cyto- and chemokines, including macrophage chemoattractant 
protein 1 (MCP-1), interleukin 6 (IL 6), transforming growth factor ß (TGF-β), 
platelet-derived growth factor (PDGF), insulin-like growth factor-1 (IGF-1), basic 
fibroblast growth factor (bFGF), and members of the epidermal growth factor 
(EGF) family. Except for TGF-β that stimulates collagen synthesis (Libby, 2002), 
these factors enhance VSMC proliferation and migration and support 
inflammation (Schmidt-Ott et al., 2000).  
IL 6 in particular has been implicated in activation of matrix metalloproteinases 
(Schmidt-Ott et al., 2000), although direct effects of Ang II on matrix 
metalloproteinase expression in VSMCs have been reported as well (Takagishi 
et al., 1995). This is an important aspect of Ang II signalling as 
metalloproteinase activity in the fibrous cap of atherosclerotic lesion has been 
associated with plaque rupture (Schmidt-Ott et al., 2000). 
Moreover, Ang II triggers changes in extracellular matrix (ECM) composition. 
Quiescent, contractile VSMCs synthesise little amounts of ECM, but phenotype 
modulation occurring during vascular remodelling substantially increases 
synthesis of fibronectin, collagen and elastin. Of interest, these changes in the 
extracellular environment favour proliferation and migration of VSMCs (Schmidt-
Ott et al., 2000).  
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5 EGF-Receptor transactivation 
Besides being activated by ligand binding, the EGF-R can be transactivated by 
a growing number of different pathways, including GPCRs, cytokine receptors 
and ion channels (Hackel et al., 1999). In this regard, EGF-R transactivation 
through the AT1-R has been proposed to play an important role in early Ang II-
signalling (Ushio-Fukai et al., 2001a; Saito et al., 2002; Eguchi et al., 1998). 
5.1 EGF-Receptors 
The EGF-Receptor (EGF-R, also termed HER1/ErbB-1) is a member of the 
EGF-R (ErbB/HER) subfamily of receptor tyrosine kinases and was the first 
receptor tyrosine kinase to be discovered (Carpenter et al., 1978).  
It is a 1186 amino acid transmembrane glycoprotein, whose intracellular part 
can be grouped into three domains: the iuxtamembrane domain serves as a site 
for feedback attenuation by protein kinase C and Erk 1/2. It is flanked by a 
kinase domain that is, in turn, followed by a carboxy-terminal tail that functions 
as an autoinhibitory substrate. Its autophosphorylation is a prerequisite for 
kinase activation. These phospho-sites are also important for further signal 
transduction, as they serve as docking sites for signalling molecules containing 
phospho-tyrosine binding domains (Wells, 1999).  
Ligand binding to the extracellular domain induces conformational changes, 
resulting in the exposure of a receptor-receptor interaction site and, 
consequently, dimerisation of two ligand-occupied EGF-Rs. Dimerisation is 
possible with all three other EGF-R family members and facilitates inter-
molecular autophosphorylation that finally leads to complete tyrosine kinase 
activation (Schlessinger, 2002).  
5.2 EGF-R transactivation by the AT1-R 
Although the EGF-R is not well characterised in terms of its role in vascular 
biology, its transactivation has been shown to occur in response to stimulation 
of the AT1 receptor in VSMCs (see Fig. 3). Importantly, a role for this link has 
been established regarding Ang II-induced activation of the mitogen activated 
protein kinases (MAPKs) extracellular-signal regulated kinase 1/2 (Erk 1/2) and 
p38 (Eguchi et al., 2001; Frank et al., 2001), and the serine/threonine kinases 
Akt and p70 S6 kinase (p70S6k) (Eguchi et al., 1999b). 
Based on the rapid onset of EGF-R phosphorylation as well as the apparent 
lack of EGF-R ligands in conditioned medium, EGF-R transactivation was 
initially thought to be mediated exclusively by intracellular events (Daub et al., 
1997). Regarding Ang II signalling in VSMCs, the tyrosine kinase c-Src, 
Ca2+-dependent activation of proline-rich tyrosine kinase 2 (PYK 2) and ROS 
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have been implicated (Eguchi et al., 1999a; Bokemeyer et al., 2000; Ushio-
Fukai et al., 2001a).  
More recent studies, however, provide evidence that cleavage of 
heparin-binding EGF-like growth factor (HB-EGF) from its membrane-anchored 
precursor is involved in mediating GPCR-induced EGF-R transactivation as well 
(Kalmes et al., 2001). HB-EGF holds, in addition to its EGF-like unit, a heparin-
binding domain that binds to heparan sulfate side chains in cell surface heparan 
sulfate proteoglycans which serve as co-activators for efficient EGF-R 
activation. Most interestingly, HB-EGF has been implicated in VSMC 
hyperplasia and atherosclerosis (Raab and Klagsbrun, 1997). 
Additionally, Ushio-Fukai et al. have shown an involvement of caveolae and 
focal adhesions in Ang II-induced EGF-R transactivation (Ushio-Fukai et al., 
2001b). 
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Fig. 3. Mechanisms discussed for Ang II-induced EGF-R transactivation. Intra- as well as 
extracellular events are required for transactivation. Information for this cartoon was obtained 
from (Ushio-Fukai et al., 2001a), (Eguchi et al., 2001), and (Eguchi et al., 1999a). 
6 Phosphoinositide 3-kinases 
6.1 Phosphoinositides 
PtdIns consists of a glycerol backbone with fatty acids attached at position 1 
and 2 (1-stearoyl, 2-arachidonyl in the naturally occurring form), and an inositol 
1-phosphate group at position 3 (Alessi, 2001). In cells, the inositol residue can 
be phosphorylated in position 3, 4 and 5, and the phosphorylated derivates are 
then referred to as phosphoinositides (Vanhaesebroeck and Alessi, 2000). 
Possible cellular functions of these phospholipids are 1), to serve as a substrate 
for phospholipases to generate soluble IP3 as second messenger, 2), the 
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interaction with intracellular proteins and 3) the alteration of membrane topology 
(Fruman et al., 1998). 
6.2 Phosphoinositide 3-kinases- classification and activation 
Enzymes capable of transferring phosphates to phosphatidylinositol or 
phosphoinositides can be divided into three general families: 
phosphoinositide 3-kinases (PI3-k), phosphatidylinositol 4-kinases and 
phosphatidylinositol-phosphat kinases. Among the three PI3-k isoforms 
identified so far, only class I PI3-k have been shown to activate the serine-
threonine kinase Akt (see 7.1.) and are therefore relevant for this work 
(Vanhaesebroeck and Alessi, 2000).  
Interestingly, quiescent cells contain significant levels of PtdIns(3)P, but hardly 
any other 3-phosphorylated phosphoinositides. The latter, however, increase 
dramatically after cellular stimulation (Vanhaesebroeck et al., 2001). In vivo, 
class I PI3-k seem to phosphorylate predominantly PtdIns(4,5)P2, generating 
PtdIns(3,4,5)P3. The second product of class I PI3-k activity, PtdIns(3,4)P2, 
originates most likely from subsequent dephosphorylation accomplished by the 
phosphatases SHIP 1 and SHIP 2 (Cantley, 2002). Of note, class I PI3-k have 
also intrinsic protein kinase activity (Fruman et al., 1998). 
Class I PI3-kinases can be divided into 2 classes, class IA and class IB. 
Class IB PI3-k are activated by the Gβγ subunit of heterotrimeric G proteins and 
show restricted tissue distribution, being abundant only in leukocytes. Class IA 
PI3-k, in contrast, are widely expressed. They are heterodimeric proteins 
consisting of a 110 kDa regulatory subunit expressed in three isoforms (p110α, 
p110β, p110δ) and a 50-85 kDa regulatory subunit of which p85 is the 
prototype. The regulatory subunit does not have intrinsic kinase activity but 
provides various sites of interaction with other signalling molecules important for 
PI3-k activation. It contains a Src homology 3 (SH3) domain, a breakpoint-
cluster-region, two proline-rich regions as well as two C-terminal SH2 domains 
spaced by an inter-SH2 region. The latter mediates tight binding of the p85 
subunit to the catalytic subunit (Wymann and Pirola, 1998). Binding of the SH2 
domains to phospho-tyrosine, created for example on receptor tyrosine kinases 
upon growth factor stimulation, targets PI3-kinase to the membrane and 
increases its activity, suggesting that phosphopeptide-SH2 binding induces 
conformational strains that propagate to the catalytic subunit via the inter-SH2 
domain (Wymann and Pirola, 1998).  
Apart from recruitment to the plasma membrane and activation via its SH2 
domains, p85 contributes to activation of class IA PI3-k by binding of the p85 
subunit to various other signalling molecules. (Wymann and Pirola, 1998). 
Whether tyrosine phosphorylation of p85 also contributes to PI3-k activation is 
discussed controversially (Saward and Zahradka, 1997; von Willebrand et al., 
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1998). Furthermore, binding of GTP-loaded Ras to the catalytic subunit seems 
to increase PI3-k activity (Fruman et al., 1998; Wymann and Pirola, 1998). 
PI3-k signalling is terminated by the action of PTEN, a phosphatase that 
dephosphorylates PtdIns(3,4,5)P3 at position 3. Loss of PTEN has been found 
in a large fraction of advanced human cancers, indicating that uncontrolled 
PI3-k signalling contributes to cancer (Cantley, 2002).  
6.3 Inhibitors of phosphoinositide 3-kinases 
Wortmannin and LY294002 are two structurally unrelated, cell permeable 
inhibitors of PI3-k. Wortmannin irreversibly inhibits the enzyme by covalent 
modification of the catalytic subunit (Wymann et al., 1996). LY294002 is a 
competitive inhibitor of the ATP binding site. Both inhibitors affect other related 
kinases when applied at concentrations higher than those required for inhibiton 
of PI3-k (Fruman et al., 1998).  
7 Akt, p70S6 kinase and MAPK 
7.1 Akt kinase 
Akt (also termed PKB due to sequence homologies with PKA and PKC) is the 
cellular homologue of the transforming oncogene of the AKT8 oncovirus and 
exists in 3 isoforms (Datta et al., 1999; Scheid and Woodgett, 2001). It is a 
serine/threonine kinase whose activation depends on the generation of 
3-phosphorylated phosphoinositides generated by class I PI3-kinases. These 
lipids interact with the pleckstrin homology (PH) domain present in the amino-
terminus of Akt, thereby recruiting Akt to the membrane (Scheid and Woodgett, 
2001).  
Translocation brings the enzyme into proximity with other PH-domain-containing 
enzymes such as the protein kinase PDK 1 (3-phosphoinositide-dependent 
kinase 1). This kinase phosphorylates Akt at threonine308 in the activation loop, 
thereby enabling binding of ATP and substrate. For full kinase activation, 
additional phosphorylation on serine473 is necessary, but the kinase responsible, 
termed PDK 2, is still not identified. Possible candidates are PDK 1 and Akt 
itself (Toker and Newton, 2000; Brazil and Hemmings, 2001) (see Fig. 4).  
Akt kinase is inactivated by the action of the serine/threonine phosphatase 
PP2A (Millward et al., 1999). 
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Fig. 4. Aktivation of Akt kinase downstream of the EGF-R. Recruitment of PI3-k to the activated 
EGF-R via the adapter complex Grb 2/Gab 1 generates 3-phosphorylated phosphoinositides on 
the membrane. These recruit Akt via its PH domain. At the membrane, Akt is phosphorylated by 
PDK 1 and a yet unidentified kinase to yield active Akt that translocates to the cytosol and the 
nucleus.  Adapted from (Vanhaesebroeck and Alessi, 2000). 
One of the first Akt substrates (for overview, see Fig. 5) identified was glycogen 
synthase kinase 3 (GSK 3). Phosphorylation inactivates GSK 3, and therefore 
stabilises or activates GSK 3 targets such as cyclin D, c-Myc and glycogen 
synthase (Cohen and Frame, 2001).  
Akt favours cell survival by phosphorylation of the pro-apoptotic protein BAD 
and caspase 9 (Datta et al., 1999).  
Additional Akt targets comprise the FOXO family of forkhead transcription 
factors. Phosphorylation of these transcription factors that enhance for example 
transcription of the cell cycle inhibitor p27Kip1, results in inactivation by 
cytoplasmatic retention or inhibition of DNA binding (Burgering and Kops, 2002; 
Scheid and Woodgett, 2001).  
Akt promotes protein synthesis by phosphorylation and activation of mTor 
(mammalian target of rapamycin) and GSK 3-dependent activation of eukaryotic 
initiation factor 2B (eIF2B) (Scott et al., 1998; Cohen and Frame, 2001). 
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Akt-mediated phosphorylation and inactivation of Raf is the basis for cross-talk 
between the Akt and the Erk 1/2 pathway and leads to inhibition of the latter 
(Zimmermann and Moelling, 1999; Reusch et al., 2001). 
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Fig. 5. Selected Akt targets and their impact on cell physiology. Akt activity results in either 
activation ( -> ) or inhibition ( -| ) of its immediate downstream targets.  
7.2 p70S6k 
p70S6K and its nuclear 85 kDa isoform are serine/threonine kinases that 
phosphorylate the S6 protein of the small 40S subunit of the ribosome at 
multiple sites. Since the discovery of a new homologue, S6K2, both isoforms 
are now termed S6K1 (Dufner and Thomas, 1999).  
Phosphorylation of the S6 protein increases translation of mRNAs that have an 
oligopyrimidine tract at their transcriptional start site (Dufner and Thomas, 
1999), although recent data suggest translational activation of these mRNAs 
independent of S6K1 activity and S6 phosphorylation (Stolovich et al., 2002). 
mRNAs containing an oligopyrimidine tract encode for many components of the 
translational apparatus (Pullen and Thomas, 1997).  
p70S6k activation requires multiple phosphorylation accomplished by various 
kinases, including mTOR, atypical PKC and PDK 1 (Dufner and Thomas, 1999; 
Scott et al., 1998).  
In VSMCs, rapamycin-inhibitable Ang II mediated activation of p70S6k has been 
shown to be implicated in protein synthesis (Giasson and Meloche, 1995). 
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7.3 MAPK 
MAPK are ubiquitously expressed serine/threonine kinases that control a variety 
of physiological processes, including cell growth, transformation, differentiation 
and apoptosis. For activation, these kinases require dual phosphorylation on 
threonine and tyrosine. Inactivation occurs by the action of specific MAPK 
phosphatases. In this way, the balance between phosphorylation and 
dephosphorylation regulates MAPK activity, allowing the cell to rapidly adjust to 
environmental changes (Johnson and Lapadat, 2002). 
MAPK are part of a signalling cascade that consists of three subsequently 
activated kinases: MAPK are phosphorylated and activated by MAPK kinases 
(MKK or MEK), which are in turn activated by MAPK kinase kinases (MKKK or 
MEKK) (see Fig. 6). Main targets of the MAPK are other protein kinases, 
phospholipases and, of importance, transcription factors (Johnson and Lapadat, 
2002).  
So far, there are three well characterised subfamilies of MAPK:  
1) the extracellular-signal regulated kinases Erk 1 and Erk 2. Erk 1/2 is 
essentially involved in proliferation after stimulation with mitogenic agents. 
Targets include the transcription factors Elk 1 and c-Myc and the p90 ribosomal 
S6 kinase (Takahashi and Berk, 1998).  
2) the c-Jun N-terminal kinases (JNK) 1, 2 and 3. JNKs are stress-activated 
protein kinases that activate the transcription factor c-Jun, a component of the 
AP-1 transcription factor (Takahashi and Berk, 1998). 
3) four p38 isoenzymes termed p38α, β, γ and δ. p38 is activated by a similar 
range of stimuli than JNK, and seems to overlap with JNK in some but not all 
functions (Takahashi and Berk, 1998). 
In VSMCs, Ang II leads to a rapid activation of all three MAPK subfamilies. An 
additional MAPK familiy, Erk 5 (BMK1) has been recently identified (Takahashi 
and Berk, 1998). 
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Fig. 6. The MAPK cascade, explained by the example of Ang II mediated activation of the 
MAPK Erk 1/2 in VSMCs. Binding of Ang II to the AT1-R leads to transactivation of the EGF-R 
(see 5.2) that recruits adapter proteins such as Shc and Grb 2. Grb 2 is constitutively 
associated with the Guanin-nucleotide exchange factor Sos that activates the small molecular 
weight GTP-binding protein Ras. Ras, in its GTP-bound state, recruits and activates the MKKK 
Raf-1, initiating the MAPK cascade. Additionally, Ras-independent, PKC-dependent pathways 
of Erk 1/2 activation have been described (Takahashi et al., 1997; Liao et al., 1997). 
8 c-Src kinase 
c-Src is the cellular counterpart of the retroviral oncogene v-Src, discovered 
more than 30 years ago in the Rous sarcoma virus (Martin, 2001). It is a part of 
the Src family of non-receptor tyrosine kinases that consists of 9 members, 
although only c-Src, Fyn and Yes are ubiquitously expressed. Myristoylation at 
the N-terminus mediates membrane localisation. Other functional domains are, 
starting from the N-terminus, a unique domain, a SH3 domain, a SH2 domain, a 
catalytic domain and a short C-terminus that is truncated in v-Src and essential 
for kinase regulation (Hubbard and Till, 2000; Martin, 2001).  
c-Src kinase activity is regulated in diverse modes (seen Fig. 7). 
Phosphorylation at tyrosine529 (numbers are specific to human c-Src) in the C-
terminus results in kinase inactivation caused by intramolecular interactions with 
the SH2 domain. This inhibitory interaction can be abolished by 
dephosphorylation, by phosphorylation of tyrosine215 in the SH2 domain or by 
binding of the SH2 domain to a ligand with greater affinity (Martin, 2001; Stover 
et al., 1996). Interaction of the SH3 domain and the linker between the SH2 
domain and the kinase domain further stabilise the inactive conformation. 
Similar to the SH2 domain, displacement due to binding of a ligand with higher 
affinity to SH3 contributes to kinase activation (Abram and Courtneidge, 2000). 
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Disrupting the inactive conformation by perturbation of intramolecular 
interactions permits intermolecular autophosphorylation of tyrosine418, an event 
that is necessary for full kinase activation (Abram and Courtneidge, 2000).  
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Fig. 7. Regulation of c-Src kinase activity. Adapted from (Martin, 2001). 
9 Cell Cycle 
The eucaryotic cell cycle consists of four distinct stages: G1-phase 
(presynthetic), S-phase (synthetic), G2-phase (premitotic) and M-phase (mitotic) 
(see Fig. 8). Quiescent cells are in so-called G0-phase and enter the cell cycle 
upon mitogenic stimulation. In the G1-phase of the cell cycle, mitogenic and 
anti-mitogenic signals are integrated and the decision is made whether to 
continue, exit or pause the cell cycle. In this regard, hyperphosphorylation of the 
Rb by cyclin E-dependent kinases is an important checkpoint. Once overcome, 
the cells are committed to further progress through the cell cycle, independent 
of extracellular stimuli (Johnson and Walker, 1999). 
9.1 Regulation of G1-phase 
G1-phase is under the control of so-called cyclin-dependent kinases (cdk). 
These assemble with cyclins, proteins that are sequentially synthesised and 
degraded throughout the cell cycle. To be fully activated, cdk/cyclin complexes 
require phosphorylation by a cdk-activating kinase (CAK) after entering the 
nucleus (Sherr and Roberts, 1999).  
D-type cyclins are the first to be induced after exposure of cells to mitogenic 
stimuli: Erk 1/2 increases transcription of the cyclin D gene and post-
translationally regulates its assembly with cdk4 or 6. Activated Akt, on the other 
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hand, prevents cyclin D degradation by inhibiting its GSK 3-dependent 
phosphorylation and subsequent degradation. Thus, mitogens exert their impact 
on cell cycle progression predominantly via D-type cyclins (see also Fig. 8).  
The cyclin D-dependent kinases cdk4 and 6 phosphorylate the Rb, that is part 
of the pocket protein family (Sherr and Roberts, 1999). Rb, in its 
hypophosphorylated, active state, binds to promoter-bound members of the E2F 
family of transcription factors, inhibiting their transcriptional activation and, thus, 
transcription of E2F-responsive genes. These encode for many components of 
the replication machinery, including cyclin E and DNA polymerase α. 
Additionally, Rb actively represses transcription by recruiting histone-modifying 
enzymes such as histone deacetylases and a histon methylase (Nielsen et al., 
2001; Trimarchi and Lees, 2002; DePinho, 1998). Phosphorylation of Rb, which 
releases E2F from transcriptional restraint, is initiated by cyclin D/cdk4/6 and 
completed by cyclin E/cdk2 (Sherr, 1996).  
Cyclin E/cdk2 complexes have broader substrate specificity and phosphorylate, 
in addition to Rb, also several proteins at replication origins as well as the cdk-
inhibitor p27Kip1, leading to degradation of the latter (Sherr, 1996). The second 
cyclin partner for cdk2, cyclin A, is synthesised not before late G1, and although 
cyclin A/cdk2 complexes share some targets with cyclin E/cdk2, they 
additionally inhibit E2F-binding to DNA in S-phase (Sherr, 1996).  
9.2 Inhibitors of cyclin-dependent kinases 
There are two families of cyclin-dependent kinase inhibitors. INK4 proteins 
(Inhibitors of CDK4) specifically inhibit the catalytic subunits of cdk4/6. In 
contrast, the so-called Cip/Kip proteins, p21Cip1, p27Kip1 and p57Kip2, affect the 
catalytic activity of cyclin D-, E- and A-dependent kinases by binding of both the 
catalytic and the cyclin subunit (Sherr and Roberts, 1999).  
For a long time, Cip/Kip proteins were thought to be exclusively inhibitory, but 
recent data provide a more differentiated view: although still being considered 
potent inhibitors of cyclin A- and E-dependent cdk2, there is increasing 
evidence that Cip/Kip proteins act as positive regulators of cyclin D-dependent 
kinase activity (Cheng et al., 1999). Interestingly, this hypothesis implies that 
cyclin D-dependent kinases contribute to cell cycle progression not only by 
phosphorylating Rb but also by complexing Cip/Kip proteins, thereby leading to 
an indirect activation of cyclin E- and A-dependent kinases (Cheng et al., 1999).  
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Fig. 8. Cell cycle phases and proteins involved in regulation of G1-phase. R = restriction point 
9.3 p53 
p53 is a prototype checkpoint protein, not required for normal cellular 
proliferation but indispensable for the ability to arrest cell cycle progression in 
response to stress conditions. In fact, it is the gene most frequently altered in 
human cancers, with an incidence of about 50% (Vousden and Lu, 2002).  
Regulation of p53 protein levels occurs predominantly by post-translational 
mechanisms. The major player in regulating p53 protein levels is Mdm2. This 
protein inhibits transcription of p53-regulated genes by binding to the 
transactivation domain of p53. Moreover, it functions as a p53-specific 
E3 ubiquitin ligase, promoting p53 degradation and limiting its half life to 
sometimes as short as a few minutes. Interestingly, Mdm2 is part of an 
autoregulatory loop as it is itsself a p53-regulated gene (Oren, 1999). Disruption 
of the Mdm2/p53 interaction, for example by phosphorylation of p53 in its Mdm2 
binding region (Schon et al., 2002) or by binding of p19ARF to Mdm2, stabilises 
p53 (Sherr, 2001; Sherr, 1998; Oren, 1999).  
p53–regulated genes are numerous and involved in apotosis, cell-cycle arrest 
and DNA repair, angiogenesis and autoregulation. In apoptosis, contribution of 
p53-mediated transcriptional repression is discussed as well (Vousden and Lu, 
2002). 
Regulation of the final outcome of p53 activation in a cell, namely apoptosis or 
just cell cycle arrest, is very complex and only partially understood: different 
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p53-affinity of the various promoters, covalent modification of the p53 protein, 
subcellular localisation as well as the availability of cofactors and p53-binding 
proteins that may contribute to the apoptotic response seem to play a role 
(Ryan and Vousden, 2002; Vousden and Lu, 2002). 
9.4 The cell cycle as a therapeutic target in cardiovascular disease 
Mitogenic stimuli trigger different signalling pathways, but all finally converge at 
the cell cycle. Therefore, the cell cycle provides a promising target for 
therapeutic intervention, reflected also by the various approaches that have 
been made in recent years, especially for preventing in-stent restenosis or 
bypass graft failure. One strategy was to limit VSMC proliferation by application 
of antiproliferative drugs such as heparins, ACE-inhibitors or growth factor 
antagonists, but clinical trials generally failed to reproduce results obtained in 
animal studies (Dzau et al., 2002).  
Local delivery of cytostatic or cytotoxic agents has proved more successful. 
Although radiotherapy and paclitaxel are able to reduce stenosis (Grise et al., 
2002; Teirstein et al., 1997; Dzau et al., 2002), so far, the most promising agent 
seems to be rapamycin (Sirolimus). This substance selectively inhibits mTor 
and exerts its antiproliferative properties by reduction of translation and 
stabilisation of p27Kip1(Vinals et al., 1999; Graves et al., 1995; Dzau et al., 
2002). In a recent trial comparing rapamycin-coated stents to uncoated stents, 
no restenosis (as defined by luminal narrowing of at least 50%) was seen in the 
rapamycin group, in contrast to 27% in the control group after 6 months (Morice 
et al., 2002).  
A third strategy is local gene therapy, and antisense oligodeoxynucleotides 
(ODN) for cell cycle regulatory genes such as c-myc, PCNA and different cdks 
have been successfully tried in animal models (Dzau et al., 2002). Moreover, 
decoy ODNs for E2F have proved save and efficacious in human trials (Mann et 
al., 1999; Mangi and Dzau, 2001; Dzau et al., 2002). 
Taken together, local application of agents capable of preventing VSMC 
proliferation seems to be a promising approach for preventing restenosis and 
vein bypass graft failure. However, this strategy is probably not feasible for 
treatment of atherosclerosis in general, as proliferation, in that case, is not 
temporally and spatially limited. Moreover, there is considerable risk that 
apoptosis of plaque VSMCs may result in plaque instability and rupture (Dzau et 
al., 2002). 
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C. Materials and Methods 
1 Preparation of major stock solutions 
Preparation of Ang II solution 
Ang II (Sigma) was dissolved in 0.25% BSA solution (Roche) and stored at 
-80°C as a 2 mM stock solution. Working aliquots were obtained by diluting 
stock solutions in 0.25% BSA to a concentration of 20 µM and stored at –20°C. 
For experiments, 100 nM Ang II were used. 
Preparation of EGF solution  
100 µg/ml stock solutions of EGF (Upstate) were prepared in PBS and stored at 
–20°C. For experiments, 100 ng/ml EGF were used. 
Calf serum 
Calf serum (Life Technologies) was heat inactivated for 40 minutes at 55°C and 
stored at –20°C. 
Resveratrol 
50 or 100 mM stock solutions of trans-Resveratrol (Sigma) were prepared in 
DMSO and stored in 10 µl aliquots at –20°C.  
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2 Cell culture 
2.1 Solutions 
PBS: PBS+ 
Na2HPO4  1.48 g   NaCl   8.00 g 
KH2PO4  0.43 g   KCl   0.20 g 
NaCl  7.20 g   Na2HPO4  1.15 g 
H2O    ad 1000 ml  KH2PO4  0.20 g 
 MgCl2 x 6 H20 0.10 g 
 CaCl2  0.10 g 
 H2O  ad 1000 ml 
 
Trypsin/EDTA: 
Trypsin (diluted 1:250 in  PBS)  0.05 g 
EDTA     0.20 g 
PBS    ad 100 ml 
 
Digestion buffer 
Collagenase (253 U/ mg)  0.100 g 
(Biochrom) 
HEPES     0.240 g 
Ascorbic acid   0.005 g 
BSA     0.100 g 
Ham`s F12 medium  ad 100 ml 
(Pan biotech) 
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2.2 Cell isolation 
VSMCs were isolated from male Sprague-Dawley rat (Charles River Wiga) 
thoracic aortas by enzymatic digestion. Aortas were removed and placed in 
PBS+ for further processing. Briefly, they were cut open and placed in digestion 
buffer (adapted from (Palmberg et al., 1985) for 15 minutes at 37°C before 
scraping off the endothelium and adventitia. Aortas were then minced and 
incubated in digestion buffer for an additional 4 hours at 37°C. After 
centrifugation, cells were placed in a 25 cm2 flask and grown in DMEM without 
phenol red (Bio Whittaker) supplemented with 10% calf serum (Invitrogen), 
2 mM glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin (growth 
medium). A minimum of four aortas is needed for one 25 cm2 flask. VSMCs 
were identified by FACS analysis and fluorescence microscopy using a 
monoclonal anti-α-smooth muscle actin FITC-conjugated antibody (1:250 
dilution, Sigma) (Chamley-Campbell et al., 1979). Human Umbilical Vein 
Endothelial cells (HUVEC), Raw 264.7 cells and L929 murine fibroblasts were 
used as negative controls to test the specifity of the antibody. However, for most 
experiments, VSMCs kindly provided by Prof. Kathy K. Griendling, Emory 
University, Atlanta, isolated by the same method, were used. 
2.3 Passaging of VSMCs 
Cells were passaged twice a week. Growth medium was removed and cells 
were washed once with 2 ml of Trypsin/EDTA solution before incubation with 
Trypsin/EDTA solution for approximately 5 minutes to allow detachment of the 
cells. Cells were subcultured 1:5 in 75 cm2 culture flasks or in appropriate 
plates. For experiments, cells between passage  7 and 15 were cultured in 6- or 
24-well plates or 60 mm dishes and used at 70-90% confluence.  
When Ang II or EGF were used for stimulation, cells were serum-starved in 
Dulbecco`s Modified Eagle`s Medium (DMEM) containing 0.1% calf serum over 
night prior to experiments. For serum-stimulation, cells were made quiescent by 
incubation in DMEM without calf serum for at least 24 hours.  
2.4 Freezing, storage and thawing of VSMCs 
For freezing, VSMCs from one 75 cm2 flask were trypsinised, spun down and 
resuspended in ice-cold freezing medium (1.1 ml DMSO, 8 ml DMEM, 2 ml calf 
serum). 1 ml aliquots were frozen in cryovials first at -20°C for one day, then at 
-80°C over night before long time storage at -196°C in liquid nitrogen. For 
thawing, cells were warmed to 37°C and immediately dissolved in pre-warmed 
culture medium. After centrifugation, cells were resuspended in culture medium 
and placed in a 75 cm2 flask.  
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3 Detection of cell death and cell viability 
When substances such as resveratrol are used for experiments, induction of 
cell death should be ruled out as a possible cause of their molecular effects. 
Accordingly, we performed various experiments to make sure that resveratrol 
showed no cytotoxicity at the concentrations used. Since resveratrol displayed 
no cytotoxicity in any of the tests listed below, the data are not shown in the 
Results section.  
Two distinct forms of eukaryotic cell death can be distinguished by 
morphological and biochemical criteria: necrosis and apoptosis.  
Necrosis is characterised by cell swelling and plasma membrane rupture, 
denaturation and coagulation of cytoplasmatic proteins and breakdown of cell 
organelles. It is caused, for example, by stresses such as ischemia or chemical 
injury.  
Apoptosis is, in contrast to necrosis, a tightly controlled process that is triggered 
by activation of a cellular suicide programme. It is accompanied by membrane 
blebbing, condensation of cytoplasm and the activation of a Ca2+- and Mg2+ 
dependent endonuclease as well as specific proteases.  
3.1 Apoptosis 
3.1.1 Staining of apoptotic nuclei with Hoechst 33342 
The bisbenzimidazole Hoechst 33342 is a cell permeable adenine-thymine 
specific fluorescent dye. Staining of apoptotic nuclei with Hoechst 33342 leads 
to bright blue staining of condensed chromatin that can be detected by 
fluorescence microscopy (Dive et al., 1992). 
Cells grown in 6-well plates were serum-starved over night and treated with  
50 µM (for Ang II) or 100 µM resveratrol (for calf serum) for 30 minutes prior to 
addition of Ang II or 10% calf serum. After 24 hours, medium was replaced by 1 
µg/ml Hoechst 33342 in PBS and cells were incubated at 37°C for 10 minutes. 
Subsequently, the dye was removed by washing with PBS and cells were 
visualised by fluorescence microscopy using 365 nm as excitation wavelength 
(Axiovert 25, Carl Zeiss, Jena, Germany).  
3.1.2 Nucleosome ELISA 
Fragmentation of the genomic DNA is a hallmark of apoptosis. The above-
mentioned endonuclease cleaves double-stranded DNA at the most accessible 
internucleosomal linker region, generating mono- and oligonucleosomes. 
Nucleosomal DNA is tightly complexed with core histones and is therefore 
protected from cleavage by the endonuclease.  
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Cell death detection ELISAPLUS (Roche) was used to detect mono- and 
oligonucleosomes in the cytoplasmatic fraction of cell lysates. The assay is 
based on a quantitative sandwich–enzyme-immunoassay-principle using mouse 
monoclonal antibodies directed against DNA and histones, respectively. The 
experiment was carried out as described in the manufacturer’s manual. Briefly, 
cells were seeded at low density in 96-well plates and grown for 48 hours, 
serum-starved over night and subsequently stimulated with or without 10% calf 
serum in the presence or absence of various concentrations of resveratrol. 
24 hours later cells were lysed and the lysate centrifuged for 10 minutes at 
200 g to remove cell nuclei containing unfragmented DNA. An aliquot of the 
supernatant was transferred to a streptavidin-coated microplate and incubated 
with a mixture of anti-histone-biotin antibody and anti-DNA-peroxidase antibody. 
A positive control provided by the company was included. After two hours of 
gentle shaking, unbound antibodies were carefully removed by a multiple 
washing step before addition of the peroxidase substrate 2,2`azino-di-[3-
ethylbenzthiazoline sulphonate (6)] (ABTS) and incubation for 20 minutes. 
Absorption was measured in an SLT spectra ELISA reader (SLT lab 
instruments, Crailsheim, Germany) at  415 nm against ABTS solution as blanc. 
3.2 Necrosis 
Lactate dehydrogenase (LDH) activity 
LDH activity was assessed in the medium of cells treated with resveratrol. As 
mentioned before, necrotic cell death leads to plasma membrane rupture. 
Cytoplasmatic enzymes such as LDH can therefore be detected in the 
supernatant. LDH catalyses the conversion of pyruvate to lactate. 
Concomitantly, NADH is oxidised to NAD+, and the resultant decrease of NADH 
can be assessed photometrically (Bergmeyer H.U., 1974). 
Phosphate buffer 
K2HPO4 (8.74 g/l) and KH2PO4 (6.8 g/l) solutions were used to obtain a solution 
with a pH of 7.5. Subsequently, 66 mg of pyruvate were added to 1 litre of 
buffer. 
NADH solution 
NADH-Na2 10 mg 
NaHCO3 (0.5%) 1 ml 
Cells were grown in 60 mm dishes, kept in DMEM supplemented with 0.1% calf 
serum over night and treated with resveratrol in different concentrations or 
vehicle for 30 minutes prior to stimulation with or without Ang II for 24 hours. 
600 µl of supernatant were mixed with 400 µl of phosphate buffer before 
addition of 10 µl of NADH solution. Enzyme activity was calculated based on the 
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decrease in NADH extinction (ε365nm = 3.34 mM-1 cm-1) measured with a 
Lambda Bio 20 photometer (PerkinElmer). 
3.3 Cytotoxicity/ Cell viability 
3.3.1 Propidium iodide exclusion assay 
Differential staining with propidium iodide (PI) can be used to investigate 
plasma membrane integrity of cells. In cells with intact plasma membrane, the 
DNA-intercalating dye PI is not able to enter the cell without prior 
permeabilisation. In damaged cells, however, PI pervades the plasma 
membrane and bright nuclear fluorescence can be detected. Accordingly, in 
flow cytometry, an increase in FL2 fluorescence can be observed.  
PI solution 
PI 2.5 µg 
PBS ad 1 ml  
Cells grown in 6-well plates were serum-starved over night and treated with or 
without various concentrations of resveratrol for 24 hours in the presence of 
10% calf serum. Cells were trypsinised, washed once with PBS and 
resuspended in 500 µl of PI solution. After five minutes of incubation on ice in 
the dark, cells were analysed by flow cytometry using the FL2 detector 
(FACSCalibur, BD biosciences, Heidelberg, Germany).  
3.3.2 MTT cell viability assay 
In this assay, the metabolic activity of cells is assessed. Mitochondrial reduction 
of the yellow-coloured 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) to the corresponding purple formazan can be taken as an 
indicator of cell viability (Mosmann, 1983).  
MTT solution 
MTT   5 mg 
PBS  ad 1 ml 
Cells were grown in 96-well plates for 48 hours, serum-starved over night and 
treated with various concentrations of resveratrol or vehicle before addition of 
Ang II or calf serum for 24 hours. Medium containing resveratrol was then 
carefully replaced to avoid direct reactions between resveratrol and MTT. MTT 
solution was added to each well to reach a final concentration of 0.5 mg/ml and 
incubated for 5 hours at 37°C. Subsequently, 190 µl of DMSO were added and 
the plate shaken for 2 hours in the dark. Absorption was measured in an SLT 
spectra ELISA reader (SLT labinstruments) at 550 nm. 
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4 Western blot analysis 
4.1 Solutions 
Lysis buffer 
"stock concentrate": 
HEPES 50 mM 
NaCl 50 mM 
EDTA 5 mM 
Na4P2O7 x 10 H2O 10 mM 
NaF 50 mM 
Na2VO4 1 mM 
bring volume up to 325 ml with H2O. pH at 4°C with NaOH to pH 7.5. Bring final 
volume up to 430 ml with H2O. Store at 4°C 
Prepare 1x lysis buffer just before use: 
Stock concentrate 8.6 ml 
PMSF 1 mM 
Complete 25 x (Roche) 400 µl 
Triton X-100 (10% in H2O)  1 ml  
 
SDS sample buffer  (stock solution)  SDS sample buffer (3 x) 
TRIS-HCl (pH 6.8) 37.5 ml Stock solution 850 µ 
SDS 6 g  ß-mercaptoethanol 150 µl 
Glycerol 30 ml 
Bromphenol blue 15 mg  
To prepare 1 x solution, add the appropriate amount of water to the 3 x solution 
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Resolving gel 10%  Stacking gel 
PAA solution 30% 5.0 ml PAA solution 30% 1.7 ml 
TRIS-base pH 8.8 5.75 ml TRIS-HCl, pH 6.8 1 ml 
SDS 10% 0.15 ml SDS 10% 0.1 ml 
H2O 6.1 ml H2O  7.0 ml 
TEMED  15 µl TEMED 20 µl 
APS 75 µl APS  100 µl 
 
Gels were prepared using a 30% solution of PAA/0.8% bisacrylamide. Different 
concentrations of PAA in the resolving gel were used according to the molecular 
weight of the protein of interest. Before addition of TEMED and APS, the 
solutions were vacuum-degassed for 10 minutes. 
 
Electrophoresis buffer (5 x) 
TRIS-base    15.0 g 
Glycine    72.0 g 
SDS     5.0 g 
H2O    ad   1000.0 ml 
 
Blotting buffer (5 x) Blotting buffer (1 x) 
TRIS-base 15.2 g    Blotting buffer (5 x)  200 ml 
Glycine 72.9 g Methanol 200 ml 
H2O  ad 1000.0 ml H2O 600 ml 
 
TRIS-buffered saline pH 8.0 containing 1% Tween (TBS-T) 
TRIS-base  3.0 g 
NaCl  11.1 
Tween-20   1.0 ml 
H2O  ad  1000.0 ml 
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Coomassie staining solution 
Coomassie brilliant blue G   1.5 g 
Acetic acid (100%)    50 ml 
Ethanol (96%)    225 ml 
H2O     ad 500 ml 
 
Coomassie destaining solution 
Acetic acid (100%)    100 ml 
Ethanol (96%)    335 ml 
H2O     ad 1000 ml 
4.2 Procedure 
Sample preparation 
Cells grown in 60 mm dishes were stimulated with Ang II, EGF or calf serum for 
the indicated times. If inhibitors were used (Table 1), these were preincubated 
for 30 minutes.  
When the phosphatase inhibitor okadaic acid was used, cells were pretreated 
with resveratrol, wortmannin or vehicle for 15 minutes and subsequently treated 
with okadaic acid for another 30 minutes prior to stimulation.  
For γ-irradiation experiments, cells were treated with 10 Gy for 12 hours before 
lysis. 
Cells were harvested on ice by washing twice with ice-cold PBS and addition of 
200 µl lysis buffer. After 30 minutes of incubation on ice, cells were scraped off 
and the lysates were transferred to pre-cooled eppendorf tubes. The 
homogenates were cleared by centrifugation at 14,000 g for 10 minutes at 4°C, 
the supernatants aliquoted and mixed with 3 x lysis buffer. Samples were boiled 
at  95°C for five minutes and stored at -85°C. Protein concentration in the 
supernatant was determined by the method of Bradford (Bradford, 1976). 
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Inhibitors used: 
Name Concentration  Provider 
AG 1478 250 nM Qbiogene-Alexis 
Aphidicolin 1 µM Calbiochem 
ICI 182,780 1 µM Tocris 
NAC 10 mM Sigma 
Ocadaic acid 1 µM Acros Organics 
PD98,059 20 µM Qbiogene-Alexis 
PP1 20 µM Qbiogene-Alexis 
Wortmannin 50 nM Qbiogene-Alexis 
Table 1: inhibitors 
 
Electrophoresis,  tank blotting and protein detection 
Equal amounts of protein (60 µg for Retinoblastoma protein, 20 µg for all other 
proteins) were loaded and separated by SDS-PAGE (Mini PROTEAN 3, 
Bio-Rad). Proteins were then transferred for 60 minutes at 100 V to a 
nitrocellulose membrane (Hybond ECL, Amersham Biosciences) with a Mini 
Trans-Blot Cell (Bio-Rad). After blocking with  5% non-fat dry milk (Bio-Rad) in 
TBS-T for one hour, primary antibodies (Table 2) dissolved in TBS-T containing 
5% BSA were added over night at 4°C. The next day, membranes were 
incubated with appropriate horseraddish-peroxidase conjugated secondary 
antibodies (Table 3) for one hour at room temperature. Proteins were detected 
using an enhanced chemiluminescence protein detection kit (NEN) and a Kodak 
Digital Science image station 440 cf (PerkinElmer, Rodgau-Jügesheim, 
Germany).  
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Primary antibodies used: 
Target Source Dilution Provider 
Akt rabbit 1:2000 Cell Signaling 
phospho-Akt (ser473) rabbit 1:2000 Cell Signaling 
Bax mouse 1:1000 BD Biosciences 
Erk 1/2 rabbit 1:5000 Cell Signaling 
phospho-Erk 1/2 rabbit 1:5000 Cell Signaling 
EGF-R rabbit 1:1000 Cell Signaling 
phospho-EGF-R (tyr845) rabbit 1:1000 Cell Signaling 
p21 mouse 1:1000 BD Biosciences 
p27 mouse 1:1000 BD Biosciences 
phospho-p38 rabbit 1:1000 Cell Signaling 
p53  mouse 1:1000 Cell Signaling 
phospho-p53 (ser15) rabbit 1:1000 Cell Signaling 
p70 rabbit 1:2000 Cell Signalling 
phospho-p70 (thr421/ser424) rabbit  1:2000 Cell Signalling 
p-Tyr-100 mouse 1:2000 Cell Signaling 
PI 3-kinase p85 rabbit 1:4000 Upstate  
Src rabbit 1:1000 BioSource 
phospho-Src (tyr215) rabbit 1:1000 BioSource 
phospho-Src (tyr418) rabbit 1:1000 BioSource 
Retinoblastoma protein mouse 1:1000 BD biosciences 
Table 2: primary antibodies 
 
Secondary antibodies used:  
Target Source Dilution Provider 
rabbit IgG Goat 1:20000 Jackson 
mouse IgG1 Goat 1:1000 Serotec 
Table 3: secondary antibodies 
 
Coomassie blue staining 
In order to control equal loading and transfer of proteins, gels were stained with 
Coomassie blue staining solution after blotting. Briefly, gels were incubated in 
staining solution for 30 minutes and subsequently washed 3 times for 10 
minutes in destaining solution. 
5 Immunoprecipitation 
Lysates were prepared as described in the Western blot section. After 
centrifugation, protein concentration in the supernatant was determined by the 
bicinchoninic acid assay method (Smith et al., 1985). Supernatant containing 
equal amounts of protein (200 µg for immunoprecipitation of PI3-k p85 subunit, 
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500 µg for EGF-R immunoprecipitation) were transferred to pre-cooled 
eppendorf tubes and lysis buffer was added to reach a final protein 
concentration of 1 µg/µl. 2 µl of anti-p85 or 5 µl of anti-EGF-R antibody (see 
Table 2) were added and samples were mixed overnight at 4°C. Antibodies 
were precipitated by incubation with 50 µl of washed protein A-agarose beads 
(Sigma) for 2 hours followed by centrifugation. The beads were washed three 
times with 500 µl of lysis buffer and resuspended in 25 µl of 3 x sample buffer 
(see 4.1). After addition of 25 ml of 1 x sample buffer, samples were boiled at 
95°C for 5 minutes and beads removed by centrifugation. 30 µl (for phospho-
tyrosine) or 10 µl (for p85 or EGF-R) of the samples were separated on a 7.5% 
polyacrylamide gel and transferred to a nitrocellulose membrane (100 V, 
90 minutes). Detection of proteins was performed as described under 4.2.  
6 Assessment of VSMC hypertrophy 
Hypertrophy is characterised by an increase in cell size but not in cell number. 
Therefore, protein synthesis can be taken as an indicator of hypertrophy as long 
as proliferation is excluded as a cause of increased protein synthesis. Ang II is 
known to induce hypertrophy but not hyperplasia in cultured VSMCs (Geisterfer 
et al 1998).  
6.1 [³H]leucine incorporation 
To measure protein synthesis, VSMCs grown in 6-well plates were made 
quiescent for 48 hours in DMEM containing 0.1% calf serum. After pre-
treatment with vehicle, resveratrol, wortmannin or PD 98,059 at the indicated 
concentrations for 30 minutes, cells were incubated with [³H]leucine (1 µCi/ml, 
Amersham) in the presence or absence of 100 nM Ang II for 24 hours and the 
amount of incorporated [³H]leucine was assessed. Briefly, cells were washed 
twice with ice-cold PBS and incubated with ice-cold 5% trichloroacetic acid for 
5 minutes at 4°C. After two additional washes, cells were dissolved in 1 ml 
0.4 M NaOH. Dublicate aliquots (0.4 ml) were transferred to scintilation vials, 
acidified with 0.2 ml of 1.0 M HCl and counted in 5 ml Liquiscint (Roth) in a LS 
6500 Beckman Coulter (Beckman). 
6.2 Cell counting 
To exclude that increase in [³H]leucine incorporation upon Ang II stimulation 
was due to increased proliferation, cells were seeded at a density of 
50,000 cells/well in 6-well plates, grown for 48 hours and made quiescent by 
incubation with DMEM containing 0.1% calf serum over night. Cells were then 
left untreated or stimulated for 24 hours with either 100 nM Ang II or 10% calf 
serum before counting in a Fuchs-Rosenthal-Chamber.  
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7 Cell cycle analysis 
7.1 PI staining  
PI is a DNA intercalating dye. The intensity with which a cell`s nucleus emits 
fluorescence light is direct proportional to the amount of bound PI and therefore 
to the cell`s DNA content. In this experiment, cells are permeabilised with 
Triton X-100, enabling PI to enter the cells. Flow cytometry permits individual 
evaluation of cells as they pass a laser beam in a single file within a fluid 
stream. 
Hypotonic fluorochrome solution (in PBS): 
0.1% (v/v) Triton X-100 
0.1% (w/v) sodium citrate 
50 µg/ml PI 
Cells were seeded at a density of 50,000 cells/well in 6-well plates and kept in 
growth medium for minimum 24 hours. Before experiments, cells were serum-
starved for at least four days to ensure synchronisation in G0-phase of the cell 
cycle.  
For cell cycle analysis, cells were treated with 10% calf serum for different time 
periods. For studies involving resveratrol, cells were either left untreated or 
pre-treated with various concentrations of resveratrol for 30 min before 
stimulation with 10% calf serum. Twenty-two hours later cells were trypsinised, 
washed once with PBS and resuspended in a hypotonic fluorochrome solution. 
After incubation at 4°C over night, PI-stained nuclei were analysed by flow 
cytometry (FACSCalibur, BD Biosciences).  
7.2 BrdU/7-amino-actinomycin D co-staining. 
This two-colour flow cytometric analysis permits the enumeration and 
characterisation of cells that are actively synthesising DNA (BrdU incorporation, 
FITC labeled) in terms of their cell cycle position (defined by 7-AAD staining 
intensities). 7-amino-actinomycin D (7-AAD) is used for determination of DNA 
content instead of PI in this experiment as the light emitted by 7-AAD and FITC 
does not overlap and can thus be analysed in distinct channels. 
Cells were seeded at a density of 80,000 cells/well in 6-well plates and made 
quiescent by serum withdrawal for 4 days. Cells were stimulated by addition of 
10% calf serum. After 4 hours, 1 µM aphidicolin was added and cells were 
grown for another 15 hours in the presence of  aphidicolin and 10% calf serum 
to achieve S-phase arrest. Subsequently, aphidicolin was removed by washing 
cells once with PBS before adding fresh growth medium containing 2 µM 
aphidicolin, 100 µM RV or vehicle for another 4 hours. The last 30 minutes, cells 
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were pulse labelled with 10 µM BrdU, harvested and processed as described by 
the manufacturer (BrdU Flow Kit, BD Biosciences). Briefly, cells were fixed and 
permeabilised using buffers provided by the kit, followed by treatment with 
DNAse to expose BrdU epitopes. These were labelled using FITC conjugated 
anti-BrdU specific antibodies. Additionally, DNA was stained with 7-AAD. 
Analysis was performed by flow cytometry (FACSCalibur, BD Biosciences, 
Germany). 
To determine whether resveratrol induced cell cycle block is reversible, cells 
were seeded at a density of 80,000 cells/well in 6-well plates. After serum 
starvation for 2 days, cell cycle arrest was induced by treatment with 100 µM 
resveratrol in growth medium for 19 hours. Resveratrol was removed by 
washing cells once with PBS. Afterwards, fresh growth medium with or without 
100 µM Resveratrol was added and cells were grown for another 4 hours. 
During the last 30 min, cells were pulse labelled with 10 µM BrdU and 
processed as described above. 
8 Statistical analysis 
All experiments were performed at least three times. Results are expressed as 
mean ±S.E. Statistical analysis was performed by ANOVA followed by a 
Dunnett multiple comparison test or a one-sample t test using GraphPad Prism 
version 3.02 for Windows (GraphPad Software Inc., San Diego, USA). 
P values < 0.05 were considered significant. 
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D. Results 
1 Characterisation of VSMCs 
VSMCs were isolated from rat thoracic aortas as described in the Materials and 
Methods section. Since this thesis was the first to deal with VSMCs in this 
group, evaluation of the protocol used for isolation was of considerable 
importance. Fig. 9 shows that isolated cells stained with FITC-labelled anti-α-
smooth muscle actin exhibited a bright green fluorescence, identifying them as 
VSMCs. When Human Umbilical Vein Endothelial cells (HUVEC), Raw 264.7 
cells and L929 murine fibroblasts were used in the same experimental settings, 
no staining was observed (data not shown), arguing for sufficient specificity of 
the antibody.  
 
 
 
Fig. 9. VSMCs stained with FITC-labelled anti-α-smooth muscle actin. Left panel shows a 
confocal image of one stained cell (400x), right panel shows a fluorescence microscopic image 
of a VSMC culture (100x). 
2 Influence of resveratrol on Ang II- and EGF-treated VSMCs 
2.1 VSMC hypertrophy 
2.1.1 Ang II induces hypertrophy but not hyperplasia in VSMCs 
VSMC hypertrophy is an important feature in the development of cardiovascular 
disease, and Ang II is a pivotal stimulus in this process. Consistent with results 
reported by others (Takahashi et al., 1997; Schmidt-Ott et al., 2000), Fig. 10 
shows that Ang II induces protein synthesis but not proliferation in VSMCs.  
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Fig. 10. Ang II induces hypertrophy but not hyperplasia in VSMCs. A, VSMCs were serum-
starved by incubation in DMEM containing 0.1% calf serum for 48 hours before treatment with 
1 µCi/ml [³H]leucine in the presence (+) or absence (-) of 100 nM Ang II. 24 hours later cells 
were harvested and [³H]leucine incorporation was assessed as described in Materials and 
Methods. B, cells were serum-starved over night in DMEM containing 0.1% calf serum, left 
untreated (-) or stimulated with 100 nM Ang II or 10% calf serum for 24 hours, harvested and 
counted in a Fuchs-Rosenthal chamber. Graph shows averaged data from three independent 
experiments performed in triplicate. ***p<0.001; *p<0.05 (one-sample t test) 
2.1.2  Resveratrol inhibits Ang II-induced VSMC hypertrophy 
To test whether resveratrol is able to block the increase in protein synthesis 
observed upon Ang II stimulation, cells were pre-incubated with different 
concentrations of resveratrol 30 minutes prior to stimulation with Ang II. The 
MEK 1 inhibitor PD98,059 and wortmannin, both substances previously 
described to inhibit Ang II-induced hypertrophy (Servant et al., 1996; Ushio-
Fukai et al., 1999), were used as positive controls. 
Fig. 11A clearly shows a concentration dependent decrease in Ang II-induced 
[³H]leucine incorporation in resveratrol treated cells that reaches significance at 
25 µM resveratrol. Of note, both resveratrol and wortmannin also reduced basal 
levels of protein synthesis (Fig. 11B). 
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Fig. 11. Resveratrol inhibits basal and Ang II-induced increase in [³H]leucine incorporation. A, 
VSMCs were serum-starved in DMEM supplemented with 0.1% calf serum for 48 hours, 
pre-treated with vehicle, the indicated concentrations of resveratrol (RV), 20 µM PD98,059 (PD) 
or 50 nM wortmannin (WM) for 30 minutes and subsequently stimulated with 100 nM Ang II for 
24 hours. B, VSMCs were serum-starved for 48 hours in DMEM supplemented with 0.1% calf 
serum and treated with vehicle, 50 µM RV or 50 nM WM for 24 hours. Cells were processed as 
described in Materials and Methods. * p<0.05; ***p<0.001 (ANOVA/Dunnett and one-sample t 
test) 
2.2 Phosphorylation of Akt, p38, Erk 1/2 and p70S6k 
2.2.1 Ang II induces phosphorylation of Akt, p38, Erk 1/2 and p70S6k 
The exact signalling mechanisms leading to VSMC hypertrophy are only 
partially understood. For Ang II-induced hypertrophy in VSMCs, the mitogen-
activated protein kinase (MAPK) Erk 1/2, the MAPK p38, the serine/threonine 
kinase Akt as well as p70S6k have been implicated (Ushio-Fukai et al., 1998; 
Servant et al., 1996; Ushio-Fukai et al., 1999). It is generally accepted that 
phosphorylation correlates with the activity of these kinases (Ushio-Fukai et al., 
1999; Ushio-Fukai et al., 1998; Frank et al., 2000; Weng et al., 1998). 
Therefore, we performed Western blot analysis using antibodies against 
phospho-kinases.  
As depicted in Fig. 12, Ang II treatment led to a rapid increase in 
phosphorylation of the above-mentioned kinases.  
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Fig. 12. Time course of Ang II-induced phosphorylation of Akt, p38 MAPK, Erk 1/2, and p70S6k. 
VSMCs in 0.1% calf serum were treated with 100 nM Ang II for the indicated times. Western 
blot analysis was performed as described in Materials and Methods. Panels show one 
representative Western blot out of three. 
2.2.2 Resveratrol inhibits phosphorylation of Akt, Erk 1/2 and p70S6k 
We next examined whether resveratrol affects activation of these kinases. As 
shown in Fig. 13, resveratrol inhibited Ang II-induced Akt and p70S6k 
phosphorylation. Reduction of Ang II-stimulated Erk 1/2 phosphorylation was 
less pronounced, while p38 MAPK phosphorylation was not affected at all.  
It is important to note that resveratrol alone had no effect on phosphorylation of 
these kinases (Fig. 14). 
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Fig. 13. Effect of resveratrol on Ang II-induced Akt, p70S6k, Erk 1/2 and p38 phosphorylation. 
VSMCs in 0.1% calf serum were treated with resveratrol (RV) in the indicated concentrations or 
vehicle (-) for 30 minutes and subsequently stimulated with (+) or without (-) 100 nM Ang II for 
10 minutes. Top panels show representative Western blots depicting total levels of kinases. 
Lower panels show levels of phosphorylated kinases. Graphs at the bottom represent signal 
intensities obtained by densitometric analysis of three immunoblots. *p<0.05; ***p<0.001 
(ANOVA/Dunnett) 
 
Influence of resveratrol on Ang II- and EGF-treated VSMCs 43 
p-Akt
(S473)
p-38
(T180/Y182)
p-Erk1/2
(T202/Y204)
p-p70S6k
(T421/S424)
RV - + RV - +
RV - + RV - +  
 
Fig. 14. Resveratrol does not enhance phosphorylation of Erk 1/2, p38, Akt and p70S6k. VSMCs 
were serum-starved over night and treated with (+) or without (-) 50 µM resveratrol for 40 
minutes. Panels show one representative Western blot out of two depicting levels of 
phosphorylated kinases.  
2.3 Protein phosphatase 2A 
Resveratrol was most effective in reducing Akt kinase activity, so we focused on 
this kinase in further experiments. To gain insight into whether resveratrol 
inhibits Akt phosphorylation by activation of phosphatases, we examined 
whether okadaic acid, an inhibitor of the phosphatase PP2A (Millward et al., 
1999), is able to override the observed resveratrol effect. Wortmannin, known to 
work via inhibition of phosphoinositide 3-kinase (PI3-k) rather than activation of 
phosphatases, was used as control. 
Western blot analysis clearly shows that both resveratrol and the PI3-k inhibitor 
wortmannin reduced Akt phosphorylation and that this effect was not abrogated 
by okadaic acid, even though, on first sight, the extent of inhibition was reduced 
(Fig. 15A).  
The slight increase in Akt phosphorylation in the presence of okadaic acid was, 
however, most likely caused by okadaic acid itsself, because okadaic acid alone 
enhanced phospho-Akt levels to a similar extent (Fig. 15B).  
Thus, resveratrol does not seem to act via activation of type 2A phosphatases.  
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Fig. 15. Resveratrol does not activate okadaic acid-inhibitable phosphatases. A, okadaic acid 
does not override the effects of resveratrol and wortmannin on Akt phosphorylation. VSMCs in 
0.1% calf serum were preincubated with 50 µM resveratrol (RV), 50 nM wortmannin (WM) or 
vehicle (-) for 15 minutes, subsequently treated with (+) or without (-)1 µM okadaic acid (O.A.) 
for an additional 30 minutes and finally stimulated with (+) or without (-)100 nM Ang II for 10 
minutes. B, okadaic acid itself enhances phospho-Akt levels. VSMCs in 0.1% calf serum were 
treated with (+) or without (-) 1 µM O.A. for 30 minutes before stimulation with (+) without (-) 
Ang II. Top panels show representative Western blots for total levels of Akt kinase. Lower 
panels depict levels of phosphorylated Akt. Graphs at the bottom show mean signal intensities 
obtained by densitometric analysis of four immunoblots.  
2.4 Phosphorylation of PI 3-kinase p85 subunit 
We next investigated pathways upstream of Akt kinase. PI3-k is essential for 
Akt activation and can therefore be considered a possible target (Datta et al., 
1999). Saward and Zahradka have demonstrated that Ang II stimulates tyrosine 
phosphorylation of the regulatory p85 subunit of PI3-k and, accordingly, PI3-k 
activity in porcine coronary artery VSMCs (Saward and Zahradka, 1997).  
As shown in Fig. 16A, tyrosine phosphorylation of the p85 subunit peaked at 
5 minutes of Ang II stimulation. This effect was dramatically reduced by 
pre-treating the cells with resveratrol (Fig. 16B), suggesting that resveratrol 
indeed acts upstream of Akt kinase by inhibiting PI3-k phosphorylation and 
activation. 
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Fig. 16. Resveratrol inhibits tyrosine phosphorylation of the p85 PI 3-k subunit. A, time course 
for p85 phosphorylation in response to Ang II. VSMCs in 0.1% calf serum were stimulated with 
Ang II for the indicated times. B, resveratrol prevents Ang II-induced p85 phosphorylation. 
VSMCs in 0.1% calf serum were pretreated with 50 µM resveratrol (RV) or vehicle for 30 
minutes before stimulation with Ang II for 5 minutes. Immunoprecipitation (IP) was performed as 
described in Materials and Methods. Immunoprecipitated proteins were analysed by Western 
blot (WB) using an anti-phospho-tyrosine antibody (top panels) or an anti-p85 antibody (lower 
panels). Graphs at the bottom show mean signal intensities obtained by densitometric analysis 
of three immunoblots. ***p<0.001 (A, ANOVA/Dunnett; B, one-sample t-test) 
2.5 Calf serum-induced Akt activation  
In order to investigate whether resveratrol directly inhibits PI3-k activity, we 
performed additional experiments using calf serum as a stimulus, since serum-
induced Akt activation has been shown to be PI3-k dependent as well (Jung et 
al., 2000; Andjelkovic et al., 1996).  
As a positive control, we used wortmannin, known to directly inhibit PI3-k by 
covalent modification of the enzyme`s catalytic subunit (Wymann et al., 1996). 
Interestingly, in striking contrast to wortmannin, resveratrol did not inhibit serum-
induced Akt phosphorylation at a concentration of 50 µM (Fig. 17). 
Consequently, resveratrol cannot be considered an inhibitor of PI 3-k itself.  
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Fig. 17. Resveratrol and wortmannin differently affect calf serum- and Ang II-induced Akt 
phosphorylation. A, resveratrol does not inhibit calf serum-induced Akt phosphorylation. Cells 
were treated with vehicle (-) or 50 µM resveratrol (RV) for 30 minutes before stimulation with (+) 
or without (-) 10% calf serum (CS) for 30 minutes. B, wortmannin inhibits both Ang II and calf 
serum-induced Akt phosphorylation. Quiescent VSMCs were treated with vehicle or 50 nM 
wortmannin (WM) for 30 minutes before stimulation with (+) or without (-) Ang II (10 minutes) or 
CS (30 minutes). Lysates were prepared as described in Materials and Methods. Bottom panels 
show representative Western blots for total levels of Akt kinase. Top panels depict levels of 
phosphorylated Akt.  
2.6 EGF-R transactivation 
2.6.1 Ang II-induced transactivation of the EGF-R is involved in Akt activation 
In recent years, it has become evident that G-protein coupled receptors 
transactivate receptor tyrosine kinases, which then serve as scaffold for various 
signalling molecules and mediate further signal transduction. For the AT1-R, 
transactivation of the EGF-R has been demonstrated (Kalmes et al., 2001).  
Consistently, Ang II caused a rapid increase in EGF-R phosphorylation in our 
cells that peaked at 2 minutes and remained above baseline for 10 minutes 
(Fig. 18). 
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Fig. 18. Time course of Ang II-induced EGF-R phosphorylation in VSMCs. VSMCs were 
stimulated with 100 nM Ang II for the indicated times. Lysates were immunoprecipitated (IP) 
with anti-EGF-R antibody, followed by immunoblotting (IB) with anti-phospho-tyrosine (Tyr-P, 
top panel) or anti-EGF-R antibody (lower panel). Graph at the bottom shows averaged data 
obtained by densitometric analysis of three immunoblots, expressed as fold increase in 
phosphorylation over control. ***p<0.001 (ANOVA/Dunnett) 
Previous reports present evidence that activation of Akt kinase by Ang II in 
VSMCs occurs in an EGF-R dependent manner (Ushio-Fukai et al., 2001a; 
Eguchi et al., 1999b). In order to verify that transactivation of EGF-R is 
implicated in Akt activation in our cells, we treated VSMCs with AG 1478, an 
inhibitor of intrinsic EGF-R kinase activity, prior to stimulation with Ang II.  
AG 1478 substantially decreased Akt phosphorylation (Fig. 19) but failed to 
completely abolish the signal. These data indicate that EGF-R is indeed 
important for Ang II-induced Akt phosphorylation, although parallel pathways 
should as well be taken into account.  
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Fig. 19. AG 1478 inhibits Ang II-induced Akt phosphorylation. VSMCs were pre-treated with 
vehicle or 250 nM AG 1478 before treatment with (+) or without (-) 100 nM Ang II for 10 
minutes. Lysates were prepared as described in Materials and Methods. Bottom panel shows a 
representative Western blot for total levels of Akt kinase. Top panel depicts the level of 
phosphorylated Akt. Graph at the bottom shows averaged data obtained by densitometric 
analysis of three independent experiments, expressed as fold inhibition of Ang II-induced Akt 
phosphorylation. **p<0.01 (one-sample t test) 
2.6.2 Resveratrol does not attenuate EGF-R transactivation 
Since EGF-R transactivation is indeed involved in Akt phosphorylation, we 
tested the ability of resveratrol to interfere with EGF-R transactivation. Agents 
previously described to act as inhibitors of this process (the antioxidant N-
acetyl-cysteine (NAC), PP1, an inhibitor of c-Src kinase, and AG 1478) were 
used as positive controls.  
Fig. 20 clearly shows that resveratrol, in contrast to NAC, PP1 and AG 1478, 
does not influence EGF-R transactivation. 
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Fig. 20. AG 1478, PP1 and NAC but not resveratrol attenuate Ang II-induced EGF-R 
phosphorylation. VSMCs were pre-incubated with 250 nM AG 1478 (AG), 20 µM PP1, 10 mM 
NAC or 50 µM resveratrol (RV) for 30 minutes before treatment with (+) or without (-) 100 nM 
Ang II for 2 minutes. Lysates were immunoprecipitated (IP) with anti-EGF-R antibody, followed 
by immunoblotting (IB) with anti-phospho-tyrosine (Tyr-P, top panel) or anti-EGF-R antibody 
(bottom panel). Panels show one representative Western blot out of three.  
2.7 EGF-induced Akt and Erk 1/2 activation 
EGF-R transactivation is not impeded by resveratrol. We, therefore, postulated 
that resveratrol must act downstream of EGF-R.  
2.7.1 EGF induces Akt and Erk 1/2 activation  
EGF rapidly stimulated Akt phosphorylation with a peak at 2 minutes. Erk 1/2 
phosphorylation occurred quickly but was sustained for the time period 
investigated (Fig. 21).  
Consequently, we investigated whether EGF-stimulated Akt and Erk 1/2 
activation is sensitive to resveratrol. 
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Fig. 21. Time course of EGF-induced Akt and Erk 1/2 phosphorylation. VSMCs were treated 
with (+) or without (-) 100 ng/ml EGF for the indicated times. Lysates were prepared as 
described in Materials and Methods. Panels show a representative Western blot out of three for 
levels of phosphorylated Akt or Erk 1/2.  
2.7.2 Resveratrol inhibits EGF-induced Akt phosphorylation 
Fig. 22 shows that resveratrol as well as PP1, AG 1478 and wortmannin 
strongly inhibited EGF-induced Akt phosphorylation, suggesting that resveratrol 
indeed acts downstream of EGF-R in regard of Akt activation. Interestingly, 
phosphorylation of Erk 1/2 was not significantly altered by resveratrol after EGF 
stimulation (Fig. 23).  
These results suggest that resveratrol predominantly interferes with the Akt and 
not the Erk 1/2 pathway upon stimulation with Akt or EGF.  
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Fig. 22. Effect of resveratrol, AG 1478, PP1 and wortmannin on EGF-induced Akt 
phosphorylation. VSMCs were pre-incubated with vehicle, 50 µM resveratrol (RV), 20 µM PP1, 
250 nM AG 1478 (AG), or 50 nM wortmannin (WM) for 30 minutes before treatment with (+) or 
without (-) 100 ng/ml EGF for 4 minutes. Lysates were prepared as described in Materials and 
Methods. Lower panel shows a representative Western blot for total levels of Akt kinase. Top 
panel depicts the level of phosphorylated Akt. Graph at the bottom shows averaged data 
obtained by densitometric analysis of four independent experiments, expressed as fold 
inhibition of EGF-induced phosphorylation. **p<0.01, ***p<0.001 (one-sample t test) 
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Fig. 23. Effect of resveratrol and AG 1478 on EGF-induced Erk 1/2 phosphorylation. VSMC in 
DMEM supplemented with 0.1% calf serum were pre-treated with vehicle, 50 µM resveratrol 
(RV) or 250 nM AG 1478 (AG) for 30 minutes before treatment with 100 ng/ml EGF for 
4 minutes. The top panel shows a representative Western blot for phosphorylated Erk 1/2 
kinase. The lower panel depicts total levels of Erk 1/2 kinase. Graph represents averaged data 
obtained by densitometric analysis of three (or two, for AG) independent experiments.  
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2.8 c-Src kinase 
PP1 was able to inhibit EGF-mediated Akt phosphorylation, suggesting that 
c-Src plays a role in signal transduction from the EGF-R to Akt. Resveratrol, on 
the other hand, has been described to function as an inhibitor of c-Src kinase in 
Hela cells (Yu et al., 2001). Accordingly, we investigated a possible impact of 
resveratrol on c-Src kinase.  
2.8.1 Ang II induces c-Src phosphorylation.  
We first performed a time course for Ang II-induced phosphorylation of sites 
important for regulation of c-Src kinase function. 
As shown in Fig. 24, Ang II induced a rapid increase in both tyrosine215 and 
tyrosine418 phosphorylation.  
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Fig. 24. Time course of Ang II-induced phosphorylation of c-Src kinase. VSMCs were stimulated 
with 100 nM Ang II for the indicated times. Lysates were immunoblotted with anti-phospho-c-Src 
(pY215 or pY418, lower panels) or anti-c-Src antibody (top panel). Graphs show averaged data 
obtained from densitometric analysis of three independent experiments, expressed as fold 
increase over control. *p<0.05, **p<0.01 (ANOVA/Dunnett) 
2.8.2 Effect of resveratrol on c-Src phosporylation 
We next tested a possible influence of resveratrol-treatment on phosphorylation 
of these sites. However, although resveratrol did decrease Ang II-induced 
phosphorylation of tyrosine215, there was no inhibition of tyrosine418 
phosphorylation (Fig. 25).  
Considering that tyrosine418 is subject to autophosphorylation and 
phosphorylation is a prerequisite for complete activation (Martin, 2001; 
Tatosyan and Mizenina, 2000), this result strongly suggests that resveratrol has 
no influence on Ang II-induced c-Src activity.  
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Fig. 25. Effect of resveratrol on Ang II-induced phosphorylation of c-Src. VSMCs were pre-
incubated with vehicle (-) or 50 µM resveratrol (RV) for 30 minutes prior to stimulation with 100 
nM Ang II for 3 minutes. Lysates were immunoblotted with anti-phospho-c-Src (pY215, left panel, 
or pY418, right panel) or anti-c-Src antibody (top panel on the left). Graphs show averaged data 
obtained from densitometric analysis of four independent experiments, expressed as inhibition 
of Ang II-induced phosphorylation. ***p<0.001 (one-sample t test) 
2.8.3 EGF-R tyrosine845 phosphorylation 
To further corroborate this hypothesis, we tested whether resveratrol interferes 
with phosphorylation of EGF-R tyrosin845, a target of c-Src kinase (Sato et al., 
1995;Biscardi et al., 1999). Tyrosine845 is phosphorylated upon Ang II 
stimulation ((Ushio-Fukai et al., 2001b) and data not shown), however, the 
signal was much more pronounced after EGF treatment. Therefore, in the 
experiments described below, EGF was used as a stimulus.  
EGF-R tyrosine845 was rapidly induced upon EGF stimulation (Fig. 26), and 
phosphorylation was completely abolished by pre-treatment of cells with 
AG 1478 (Fig. 27). As expected, resveratrol did not decrease EGF-R 
phosphorylation at this site (Fig. 27). 
Taken together, these results suggest that resveratrol does not attenuate c-Src 
kinase activity. 
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Fig. 26. Time course of EGF-induced EGF-R phosphorylation. VSMCs were treated with 
100 ng/ml EGF for the indicated times. Lysates were immunoblotted with anti-phospho-EGF-R 
(pY845, top panel) or anti-EGF-R antibody (lower panel). Graph shows averaged data obtained 
by densitometric analysis of three immunoblots.  
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Fig. 27. Resveratrol does not inhibit EGF-induced phosphorylation of EGF-R. VSMCs were 
treated with vehicle, 50 µM resveratrol (RV) or 250 nM AG 1478 (AG) for 30 minutes prior to 
stimulation with 100 ng/ml EGF for 2 minutes. Graph shows averaged data obtained from 
densitometric analysis of four (RV) or two (AG) independent experiments. **p<0.01 (one-sample 
t test) 
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3 Influence of resveratrol on calf serum-treated VSMCs  
3.1 Cell cycle progression  
3.1.1 Calf serum-induced cell cycle progression 
Flow cytometric cell cycle analysis revealed that VSMCs require about 10-12 
hours to reach S-phase and 22-24 hours to complete one cell cycle (Fig. 28). 
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Fig. 28. Cell cycle progression of VSMCs upon calf serum stimulation. Quiescent VSMCs were 
stimulated with 10% calf serum for the indicated times. Cells were harvested and processed as 
described in Materials and Methods. Images show one representative experiment out of three. 
3.1.2 Resveratrol inhibits VSMC proliferation 
Previous studies demonstrate an antiproliferative effect of resveratrol in various 
cancer cell lines (Ahmad et al., 2001; Sgambato et al., 2001; Hsieh and Wu, 
1999) as well as in cardiovascular cells (Zou et al., 1999; Hsieh et al., 1999).  
Consistent with these results, we observed a dose-dependent reduction of calf 
serum-induced proliferation in VSMCs treated with 1-25 µM resveratrol 
(Fig. 29). 
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Fig. 29. Resveratrol inhibits VSMC proliferation. VSMCs were serum-starved for 2 days before 
stimulation with the indicated concentrations of resveratrol (RV) in the presence of 10% calf 
serum. Fresh growth medium and resveratrol was added every day. On day four, cells were 
harvested and counted in a Fuchs-Rosenthal chamber. Graph shows averaged data from three 
independent experiments performed in triplicate normalised to non treated cells. ***p<0.001 
(ANOVA/Dunnett) 
In order to elucidate the exact mechanisms underlying the antimitogenic effect 
of resveratrol in VSMCs, flow cytometric cell cycle analysis of VSMCs treated 
with various concentrations of resveratrol for 22 hours were performed.  
The data obtained suggest a dose-dependent accumulation of resveratrol-
treated cells at the G1/S-interphase, with 100 µM resveratrol leading to a 
complete block in cell cycle progression (Fig. 30).  
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Fig. 30. Resveratrol-induced changes in cell cycle distribution of calf serum stimulated cells. 
Cells were serum-starved for four days and pre-incubated with various concentrations of 
resveratrol (RV) for 30 minutes (A, 0 µM; B, 0 µM; C, 0.1 µM; D, 1 µM; E, 10 µM; F, 100 µM). 
Subsequently, cells were stimulated with  (B-F) or without (A) 10% calf serum (CS) for 22 hours. 
Cells were harvested and nuclei stained with PI as described in Materials and Methods. Data 
show one representative experiment out of three.  
3.1.3 Resveratrol-induced cell cycle arrest is reversible 
The DNA replication block depicted in Fig. 30 was, however, reversible, as cells 
arrested by resveratrol treatment were still able to cycle through S-phase when 
resveratrol was removed (Fig. 31). 
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Fig. 31. Resveratrol-induced cell cycle arrest is reversible. Quiescent VSMCs were treated with 
100 µM resveratrol (RV) in growth medium for 19 hours. Medium was changed and cells were 
treated with (RV→RV) or without (RV→vehicle) resveratrol for four hours in the presence of 
10% calf serum. During the last 30 minutes, cells were pulse-labelled with BrdU and processed 
as described in Materials and Methods. Images show results of one representative experiment 
out of three.  
Of note, neither Hoechst, PI staining, a nucleosome ELISA, nor cell cycle 
analysis revealed cytotoxic effects at 100 µM resveratrol (data not shown and 
Fig. 30F); therefore, this concentration was used for all other cell cycle 
experiments. 
3.2 Phosphorylation of Akt, Erk 1/2 and p70S6K  
It is widely accepted that mitogens promote cell cycle progression of quiescent 
cells via the Akt and the Erk 1/2 signalling cascades, as these are critically 
involved in accumulation of D-type cyclins in the G1-phase (Sherr and Roberts, 
1999). p70S6k is activated downstream of Akt and Erk 1/2 in VSMCs (Eguchi et 
al., 1999b) and has been implicated in cell proliferation (Vinals et al., 1999). We, 
therefore, hypothesised that inhibition of these kinases might contribute to the 
observed antimitogenic effect of resveratrol.  
3.2.1 Calf serum induces phosphorylation of Akt, Erk 1/2 and p70S6k 
As shown in Fig. 32, serum stimulation led to a rapid increase in Akt, Erk 1/2 
and p70S6k phosphorylation that was sustained for several hours.  
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Fig. 32. Effect of calf serum stimulation on phosphorylation of Akt, Erk 1/2, and p70S6k. 
Quiescent VSMCs were treated with 10% calf serum (CS) for the indicated times and lysates 
were prepared as described in Materials and Methods. Top panels show one representative 
Western blot out of three for phosphorylated kinases. Lower panels show total levels of kinases. 
3.2.2 Effect of resveratrol on phosphorylation of Akt, Erk 1/2 and p70S6k 
However, resveratrol only weakly inhibited serum-mediated Akt and p70S6k 
phosphorylation and failed to significantly alter Erk 1/2 phosphorylation 
(Fig. 33). Since resveratrol affected cell cycle progression in concentrations as 
low as 10 µM and arrest was complete at 100 µM, inhibition of these kinases is 
unlikely to primarily account for this effect. 
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Fig. 33. Effect of resveratrol on serum-induced phosphorylation of Akt, Erk 1/2 and p70S6k. 
Serum-starved VSMCs were pre-incubated with resveratrol (RV) in the indicated concentrations 
for 30 minutes and subsequently stimulated with (+) or without (-) 10% calf serum (CS) for 30 
minutes. Lower panels show a representative Western blot for phosphorylated kinases. Top 
panels show total levels of kinases. Graphs at the bottom represent averaged data obtained  by 
densitometric analysis of three immunoblots and normalised to values of CS stimulated cells. 
*p<0.05 (ANOVA/Dunnett) 
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3.3 Phosphorylation of Rb 
In late G1-phase, cells reach the so-called restriction point. Beyond this point, 
cell cycle progression proceeds independent of growth factor stimulation (Sherr, 
1996). Hypophosphorylated Rb binds members of the E2F family of 
transcription factors, and thus inhibits transcription of E2F-responsive genes 
necessary for cell cycle progression. Hyperphosphorylation of Rb by 
cyclin-dependent kinases leads to dissociation of Rb from promoter-bound E2F, 
allowing transcription of E2F regulated genes (Sherr, 1996; DePinho, 1998). 
3.3.1 Calf serum increases Rb protein phosphorylation 
Fig. 34A shows that calf serum leads to a continuous increase in Rb 
hyperphosphorylation over 22 hours. Of note, it has been reported that 
antimitogenic agents affecting the G1-phase, such as inhibitors of the PI3-k or 
the p70S6k pathway, keep Rb in the hypophosphorylated, active state (Vinals et 
al., 1999). Consistently, the results of a control experiment presented in Fig. 
34B show that wortmannin decreased phosphorylation levels of Rb. 
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Fig. 34. Western blot analysis of Rb hyperphosphorylation. A, time course of Rb 
hyperphosphorylation in response to 10% calf serum. Quiescent VSMCs were stimulated with 
10% calf serum (CS) for the indicated times. Panel depicts one representative Western blot out 
of three. B, wortmannin attenuates calf serum-induced Rb hyperphosphorylation. Quiescent 
VSMCs were pre-incubated with 50 nM wortmannin (WM) for 30 minutes prior to stimulation 
with 10% CS for the indicated times. Panel shows one representative Western blot out of two.  
3.3.2 Resveratrol promotes Rb hyperphosphorylation 
We next investigated the possible impact of resveratrol on calf serum-induced 
Rb hyperphosphorylation. Most interestingly, pre-treatment of cells with 
resveratrol did not prevent Rb hyperphosphorylation but resulted in a 
substantial increase in hyperphosphorylated Rb (Fig. 35). 
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Fig. 35. Resveratrol increases Rb hyperphosphorylation. Quiescent VSMCs were pre-treated 
with 100 µM resveratrol (RV) for 30 minutes prior to addition of 10% calf serum (CS) for 22 
hours. Panel shows one representative Western for phosphorylated Rb. Graph shows averaged 
data obtained by densitometric analysis of five immunoblots.**p<0.01 (one-sample t test) 
3.4 p21Cip1 and p27Kip1 protein expression 
Several studies have linked resveratrol with an upregulation of p21Cip1 (Ahmad 
et al., 2001;Hsieh et al., 1999). Even though the Cip/Kip proteins are potent 
inhibitors of cyclin E- and A-dependent kinases, which are rate-limiting and 
essential for DNA replication, they act as positive regulators of cyclin 
D-dependent kinases that phosphorylate Rb (Sherr and Roberts, 1999). 
Therefore, it seemed possible that resveratrol may induce cell cycle arrest 
through upregulation of the cell cycle inhibitors p21Cip1 and p27Kip1.  
3.4.1 Calf serum regulation of p21Cip1 and p27Kip1 protein expression 
Fig. 36 shows time courses of p21Cip1 and p27Kip1 in calf serum-stimulated 
VSMCs. As expected, p21Cip1 levels were low in quiescent cells but up-
regulated in late G1-phase. In contrast, p27Kip1 levels decreased over time upon 
stimulation with calf serum as reported before (Sherr and Roberts, 1999).  
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Fig. 36. Time course of p21Cip1 and p27Kip1 protein expression in response to calf serum. 
Quiescent VSMCs were stimulated with 10% calf serum (CS) for the indicated times. Panels 
show one representative Western blot out of three. 
3.4.2 Resveratrol reduces levels of p21Cip1and p27Kip1 
Resveratrol, however, in contrast to results from other groups using different 
cell systems, neither induced p21Cip1 nor p27Kip1 protein expression. Quite the 
contrary, levels of these cyclin-dependent kinase inhibitors were lower in 
resveratrol-treated VSMCs (Fig. 37).  
Taken together, these results suggest that resveratrol does not affect cell cycle 
progression in the G1-phase.  
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Fig. 37. Effect of resveratrol on p21Cip1 and p27Kip1 protein expression in calf serum-stimulated 
cells. Quiescent VSMCs were pre-incubated with 100 µM resveratrol (RV) for 30 minutes before 
stimulation with 10% calf serum (CS) for 22 hours. Blots show one representative Western blot 
for p27Kip1 (left panel) or p21Cip1 (right panel). Graphs show averaged data obtained by 
densitometric analysis of four immunoblots. *p<0.05;**p<0.01 (one-sample t test)  
3.5 Cell cycle arrest in early S-phase 
Evaluation of the results obtained so far indicated that resveratrol may arrest 
VSMCs in S- and not in G1-phase. The following experiments were performed 
to verify this hypothesis.  
As demonstrated in Fig. 28, VSMCs require about 10-12 hours to reach S-
phase and 22-24h to complete one cell cycle. Therefore, we assessed levels of 
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hyperphosphorylated Rb after 12 and 22 hours of calf serum stimulation in the 
presence of resveratrol. Aphidicolin, a well characterised inhibitor of DNA 
polymerase α and δ, was used as a positive control. 
 
3.5.1 Comparison of resveratrol and aphidicolin regarding Rb hyper-
phosphorylation and p21Cip1 and p27Kip1 expression 
Neither resveratrol nor aphidicolin altered the Rb phosphorylation state until 12 
hours, consistent with the idea that both compounds do not affect G1-phase. 
However, after 22 hours, both substances clearly increased 
hyperphosphorylated forms of Rb.  
Similarly, the expression of p21Cip1 and p27Kip1 was not changed until 12 hours 
of treatment with aphidicolin or resveratrol, respectively. After 22 hours, p27Kip1 
levels appeared lower in response to both stimuli.  
Interestingly, unlike resveratrol, aphidicolin did lower p21Cip1 protein levels after 
22 hours (Fig. 38). Of note, neither resveratrol nor aphidicolin altered basal 
levels of phosphorylated Rb, p21Cip1 or p27Kip1 (Fig. 38).  
Taken together, these results suggest that resveratrol acts similarly to, but not 
identically with, the DNA polymerase inhibitor aphidicolin.  
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Fig. 38. Western blot analysis of Rb hyperphosphorylation, p21Cip1 and p27Kip1 protein 
expression. Quiescent VSMCs were treated with 100 µM resveratrol (RV), 1 µM aphidicolin 
(Aph) or vehicle for 30 minutes prior to stimulation with (+) or without (-) 10% calf serum (CS) for 
the indicated times. Panels show one representative Western blot out of three.  
3.5.2 Resveratrol prevents cell cycle progression in early S-phase 
To further corroborate the hypothesis that resveratrol causes a DNA replication 
block in S-phase, we determined whether resveratrol is still able to inhibit cell 
cycle progression when cells are already in S-phase. Therefore, we 
accumulated cells in early S-phase by employing aphidicolin. Subsequent 
treatment of released cells with resveratrol (or aphidicolin, as a positive control) 
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still prevented cells from synthesising DNA, as shown by the complete absence 
of BrdU incorporation (Fig. 39). 
Thus, resveratrol is indeed able to arrest VSMCs in early S-phase. 
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Fig. 39. Resveratrol inhibits S-phase progression of VSMCs at the G1/S-interphase. Quiescent 
VSMCs were synchronised in early S-phase by aphidicolin (Aph, 1 µM) treatment as described 
in Materials and Methods. After aphidicolin-release, cells were grown in fresh growth medium 
supplemented with 2 µM Aph, 100 µM resveratrol (RV) or vehicle for another four hours. During 
the last 30 minutes, cells were pulse labelled with BrdU and subsequently processed as 
described in Materials and Methods. Images show one representative experiment out of three.  
3.6 Serine15-phosphorylation of p53 
Gottifredi et al. have recently shown that blocked DNA replication induces 
increased levels of serine15-phosphorylated p53 that is, however, 
transcriptionally impaired as it is not accompanied by p21Cip1 accumulation 
(Gottifredi et al., 2001). We, therefore, examined whether resveratrol leads to 
an increase in levels of serine15-phosphorylated p53. Again, aphidicolin was 
used as a positive control. 
Western blots depicted in Fig. 40 show a dramatic increase in serine15-
phosphorylated p53 after resveratrol as well as aphidicolin treatment. 
Consistent with the idea that resveratrol only transiently blocks DNA synthesis, 
the increase in phosphorylated p53 was not accompanied by an increase in 
p21Cip1 (Fig. 38) or Bax (Fig. 40) levels.  
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Fig. 40. Effects of resveratrol and aphidicolin and p53 serine15 phosphorylation and Bax levels. 
Quiescent VSMCs were treated with 100 µM resveratrol (RV), 1 µM aphidicolin (Aph) or vehicle 
for 30 minutes before stimulation with (+) or without (-) 10% calf serum (CS) for the indicated 
times. Panels show one representative Western blot out of three. 
3.7 γ-irradiation 
Little is known about regulation of p53 in VSMCs. Therefore, to elucidate why 
enhanced p53 serine15 phosphorylation by resveratrol is not accompanied by 
increased expression of target genes such as p21 or Bax in these cells, we 
performed additional experiments using γ-irradiation.  
As expected, γ-irradiation alone as well as in combination with resveratrol or 
aphidicolin led to a strong increase in serine15-phosphorylated p53. However, in 
contrast to findings by Gottifredi et al. in RKO cells (Gottifredi et al., 2001), 
neither resveratrol nor aphidicolin could prevent the augmentation of p21 levels 
after γ-irradiation. Interestingly, although resveratrol, aphidicolin and γ-irradiation 
increased p53 serine15 phosphorylation in VSMCs, and γ-irradiation also p53 
transactivation, total levels of p53 were not altered (Fig. 41).  
These data suggest that γ-irradiation can rescue p53 from a transcriptional 
block induced by treatment of cells with aphidicolin or resveratrol.  
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Fig. 41. Western blot analysis of serine15 p53 levels, total p53  and p21 levels in resveratrol- or 
aphidicolin-treated and/or γ-irradiated VSMCs. Quiescent VSMCs were treated with growth 
medium containing 100 µM resveratrol (RV), 1 µM aphidicolin (Aph) or vehicle for 12 hours prior 
to γ-irradiation (IR, 10 Gy). Cells were harvested 12 hours after IR. Panels show one 
representative Western blot out of four. 
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E. Discussion 
1 Influence of resveratrol on Ang II-treated VSMCs 
Resveratrol is a polyphenolic stilbene derivate found in grape skin. It is 
proposed to be, at least in part, responsible for the beneficial cardiovascular 
effects attributed to red wine (Soleas et al., 2001; Wu et al., 2001). In this study, 
we show that resveratrol is able to attenuate VSMC hypertrophy induced by 
Ang II treatment, and provide insight into the molecular mechanisms that might 
be involved in mediating this effect. 
1.1 Inhibition of Ang II-induced VSMC hypertrophy- involvement of 
kinases 
Vascular hypertrophy is a critical determinant of vascular disease. Ang II is an 
important stimulus in this process, inducing protein synthesis but not DNA 
synthesis (Takahashi et al., 1997; Schmidt-Ott et al., 2000). Our results show 
that resveratrol attenuates [³H]leucine incorporation in Ang II-stimulated cells 
and is therefore able to reduce VSMC hypertrophy. 
The precise signalling mechanisms involved in mediating VSMC hypertrophy 
are not completely understood. However, it is known that phosphorylation and 
dephosphorylation of kinases plays an important role in regulating overall 
protein synthesis (Servant et al., 1996). Ang II activates a plethora of protein 
kinases in VSMCs (Touyz and Schiffrin, 2000). Of these, the MAPKs Erk 1/2 
and p38, the serine/threonine kinase Akt, as well as one of its downstream 
effector kinases, p70S6k (Eguchi et al., 1999b), have been shown to mediate 
Ang II-induced hypertrophy (Ushio-Fukai et al., 1998; Ushio-Fukai et al., 1999; 
Servant et al., 1996). Resveratrol attenuates phosphorylation of Erk 1/2, Akt 
and p70S6k but not p38 MAPK. In this regard, it has been shown that both the 
Erk 1/2 and the PI3-k/Akt pathway contribute to p70S6k activation in VSMCs 
(Eguchi et al., 1999b). Interestingly, our results show that inhibition of the 
downstream kinase p70S6k by resveratrol is less potent than that of Akt. This is 
probably caused by signalling from the Erk 1/2 pathway to the p70S6k, because 
resveratrol reduced Erk 1/2 phosphorylation far less effectively as it did Akt 
phosphorylation. Presumably, inhibition of both Akt and, to a lesser extent, the 
Erk 1/2 pathway, contribute to reduction of hypertrophy by resveratrol, as others 
have shown that inhibition of either pathway only partially inhibits hypertrophy 
(Servant et al., 1996).  
Regarding the mechanisms by which resveratrol may influence phosphorylation 
of Akt, two possibilities must be taken into account: either inhibition of 
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phosphorylation or activation of specific phosphatases. Akt is dephosphorylated 
and inactivated by the serine/threonine phosphatase 2A (Andjelkovic et al., 
1996; Millward et al., 1999). However, pre-treating the cells with okadaic acid, 
an inhibitor of this phosphatase (Millward et al., 1999), did not abrogate the 
inhibitory effect of resveratrol on Akt phosphorylation. Therefore, resveratrol 
does not seem to activate phosphatase 2A.  
This leaves the possibility that resveratrol acts via the PI3-k pathway, since 
PI3-k activity is essential for Akt activation in Ang II-stimulated VSMCs (Eguchi 
et al., 1999b). The PI3-k family can be divided into three classes, but for signal 
transduction upon growth factor stimulation, class IA PI3-k are most important 
(Vanhaesebroeck et al., 2001). Class IA PI3-k are heterodimeric proteins 
composed of an 85 kDa regulatory subunit that is tightly associated with a 
110 kDa catalytic subunit (Wymann and Pirola, 1998). Our results show that 
resveratrol is able to substantially reduce tyrosine phosphorylation of the PI3-k 
p85 subunit, an event previously correlated with PI3-k activity (Saward and 
Zahradka, 1997).  
The kinase responsible for tyrosine phosphorylation of p85 is not yet identified, 
but autophosphorylation by PI3-k itself is unlikely since PI3-k has been reported 
to autophosphorylate on serine residues (Wymann and Pirola, 1998). Therefore, 
we conclude that resveratrol must act further upstream of PI3-k. This hypothesis 
is corroborated by the finding that, in contrast to the PI3-k inhibitor wortmannin, 
resveratrol was not able to abrogate Akt phosphorylation induced by calf serum 
treatment, implying some specificity for Ang- and EGF-stimulated pathways.  
1.2 EGF-R transactivation 
Transactivation of the EGF-R has been shown to be essential for early Ang II 
signalling through the AT1-R (Kalmes et al., 2001). The EGF-R is a receptor 
tyrosine kinase whose kinase domain is flanked by a carboxy-terminal tail that 
functions as an autoinhibitory substrate. Carboxy-terminal autophosphorylation 
is a prerequisite for EGF-R kinase activity. In the same time, these 
autophosphorylation sites are important for initiation of downstream signalling, 
serving as docking sites for various signalling molecules and complexes (Wells, 
1999).  
Consistent with results reported by others (Ushio-Fukai et al., 2001a), we show 
a rapid increase in EGF-R phosphorylation upon Ang II stimulation. Several 
signalling pathways including Ca2+, proline-rich tyrosine kinase 2 (PYK 2), 
metalloproteinases as well as ROS and c-Src kinase have been demonstrated 
to be involved in EGF-R transactivation (Eguchi et al., 1999a; Eguchi et al., 
1998; Ushio-Fukai et al., 2001a; Bokemeyer et al., 2000; Kalmes et al., 2001). 
However, resveratrol does not interfere with Ang II-induced EGF-R 
phosphorylation, indicating that resveratrol may act downstream of EGF-R.  
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This hypothesis is substantiated by the fact that Akt phosphorylation is still 
inhibited when EGF is used for stimulation.  
1.3 Signalling downstream of EGF-R 
Studies performed in other cell systems suggest that c-Src kinase is important 
for signalling downstream of EGF-R (Stover et al., 1995; Sato et al., 1995). 
Consistently, the c-Src kinase inhibitor PP1 completely blocked EGF-induced 
Akt phosphorylation. Interestingly, in HeLa cells, resveratrol has been shown to 
act as an inhibitor of c-Src (Yu et al., 2001). Although c-Src is phosphorylated at 
various sites, phosphorylation of tyrosine418 in the kinase domain and 
tyrosine529 in the carboxy-terminus are most important in regulating its activity 
(see also Fig. 7). Phosphorylation of tyrosine529 stabilises intramolecular 
interactions between the carboxy-terminus and the SH2 domain, thereby 
repressing kinase activity. In contrast, autophosphorylation of tyrosine418 that is 
situated in the activation loop leads to increased kinase activity (Abram and 
Courtneidge, 2000). Phosphorylation on tyrosine215 in the SH2 domain has also 
been implicated in c-Src activation, impeding intramolecular binding of the 
carboxy-terminal inhibitory phospho-tyrosine529 and allowing thus kinase 
activation independent of carboxy-terminal dephosphorylation (Stover et al., 
1996).  
We found that resveratrol, although capable of attenuating phosphorylation of 
tyrosine215, has no impact on phosphorylation of tyrosine418. Tyrosine215 
phosphorylation, however, is dispensable for kinase activation. Tyrosine418, on 
the other hand, is subject to intermolecular autophosphorylation and a positive 
regulator of c-Src kinase activity (Bjorge et al., 2000). For that reason it seems 
likely that c-Src kinase in resveratrol treated cells remains active.  
This hypothesis was further confirmed by the result that EGF-induced 
phosphorylation of tyrosine845 in the kinase domain of the EGF-R is not 
impaired when cells are pre-treated with resveratrol. Tyrosine845 is a highly 
conserved residue that is phosphorylated in a c-Src dependent manner and has 
been associated with increased EGF-R kinase activity (Tice et al., 1999; 
Biscardi et al., 1999; Ushio-Fukai et al., 2001b). AG 1478 completely abolished 
phosphorylation on this site, consistent with the idea that c-Src has no access to 
this site unless the carboxy-tail is removed upon receptor autophosphorylation 
(Stover et al., 1995). These observations, together with the fact that resveratrol 
is not able to reduce EGF-R transactivation, strongly indicate that resveratrol 
does not inhibit c-Src kinase activity.  
We, therefore, postulate that resveratrol may interfere with a tyrosine kinase or 
phosphatase, as phosphorylation of tyrosine215 of c-Src and tyrosine 
phosphorylation of the p85 regulatory subunit are inhibited by this substance. It 
may also be speculated that resveratrol, although unable to inhibit overall 
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EGF-R tyrosine phosphorylation induced by Ang II, prevents phosphorylation of 
a single residue of the EGF-R or an adapter protein such as Grb 2-associated 
binder 1 (Gab 1) that is necessary for PI3-k signalling. In this regard, Zhang et 
al. have recently shown that induction of the tyrosine phosphatase Shp 2 
negatively regulates EGF-dependent PI3-k activation by selective 
dephosphorylation of p85 binding sites on Gab 1, while PI3-kinase activation by 
other growth factors is unaffected (Zhang et al., 2002). Further experiments will 
be performed in this lab to clarify a possible role of Shp 2 and Gab 1 in 
resveratrol signalling.  
2 Influence of resveratrol on calf serum-treated VSMCs 
Proliferation of VSMCs is critically involved in the development of vascular 
proliferative diseases (Braun-Dullaeus et al., 1998; Dzau et al., 2002). 
Resveratrol has been previously demonstrated to inhibit proliferation in various 
cell types (Soleas et al., 2001). This study provides insight into the molecular 
mechanisms used by resveratrol to mediate its antimitogenic effects in VSMCs. 
We demonstrate that, while G1-phase is not affected, resveratrol leads to a 
reversible arrest in the S-phase of the cell division cycle. 
2.1 Effects on Erk 1/2, p70S6k and Akt kinase phosphorylation 
Cyclin D is the first cyclin to be induced when cells progress through G1-phase. 
D-type cyclins function as a link between mitogenic stimuli and the potentially 
autonomous cell cycle machinery. In this regard, the Erk 1/2 signalling cascade 
as well as Akt governed pathways contribute to the accumulation of cyclin D 
and its assembly with cdk4 and cdk6 (Sherr and Roberts, 1999). Thus, both 
pathways play a critical role in linking mitogenic cues to the G1-phase of the cell 
cycle. p70S6k, situated downstream of Akt and Erk 1/2 (Eguchi et al., 1999b), is 
thought to be implicated in cell cycle progression due to its capacity to 
phosphorylate the ribosomal protein S6 in response to mitogens. Although cell 
cycle analysis performed by flow cytometry and previously published data (Zou 
et al., 1999) suggest that resveratrol might target G1-phase, we detected only 
slight inhibition of Akt and p70S6k phosphorylation. Erk 1/2 phosphorylation was 
not significantly altered at all, suggesting that factors other than these kinases 
mediate the antiproliferative effect of resveratrol. These results seem to contrast 
with the findings described in 1.1 showing that resveratrol inhibits 
phosphorylation of Akt, p70S6k and Erk 1/2, and with a study reporting inhibition 
of Erk 1/2 phosphorylation in endothelin-1-stimulated porcine coronary arteries 
pre-treated with resveratrol (El Mowafy and White, 1999). This apparent 
contradiction can be resolved considering the different proximal pathways 
induced by distinct stimuli. Besides that, it can be deduced that resveratrol 
targets neither of these kinases directly. 
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2.2 Effect on Rb hyperphosphorylation 
Basically all signals relevant for G1 progression into S-phase finally culminate in 
Rb hyperphosphorylation. Rb senses and integrates a multitude of proliferative 
and antiproliferative signals by interacting with members of the E2F family of 
transcription factors (Weinberg, 1995; Trimarchi and Lees, 2002). In its 
hypophosphorylated, active state Rb forms a complex with E2F thereby 
blocking its transcriptional activation, and actively represses transcription of cell 
cycle genes (DePinho, 1998; Trimarchi and Lees, 2002). Hyperphosphorylation 
of Rb that is accomplished first by cyclin D-dependent kinases in mid-G1-phase 
and then completed by cyclin E-cdk2 leads to its dissociation from promoter-
bound E2F, thus allowing transcription of E2F regulated genes (Sherr, 1996). 
Antimitogenic substances affecting  G1-phase consequently prevent Rb 
hyperphosphorylation (Vinals et al., 1999). In contrast to recent findings that 
resveratrol decreases the hyperphosphorylated form of Rb in human 
epidermoid carcinoma (A431) cells (Adhami et al., 2001), we found that in 
serum-activated VSMCs, resveratrol strongly augments Rb 
hyperphosphorylation. 
2.3 Effect on Cip/Kip proteins 
So far, all results pointed more to the possibility of a resveratrol-mediated 
putative DNA replication block in early S-phase instead of an interference in G1. 
To investigate whether resveratrol indeed arrests cells in early S-phase, we 
determined levels of Rb hyperphosphorylation caused by resveratrol and, as a 
positive control, by the DNA polymerase inhibitor aphidicolin, after 12 and 22 
hours of calf serum stimulation. As expected, neither resveratrol nor aphidicolin 
increases levels of Rb hyperphosphorylation until 12 hours. At this time point, 
cells are still at the G1/S-interphase and thus not affected by a putative S-phase 
block. After 22 hours, however, accumulation of resveratrol- or aphidicolin-
treated cells in S-phase leads to a concomitant accumulation of 
hyperphosphorylated Rb as compared to normally progressing control cells. 
Consistently, also p21Cip1 and p27Kip1 levels seem to be altered only after 
prolonged treatment, corroborating that G1 is not affected by resveratrol and 
also not, as already known, by aphidicolin. Interestingly, in contrast to 
resveratrol, aphidicolin treatment does not downregulate p21Cip1 protein levels, 
arguing against an identical mechanism of these two substances.  
2.4 Inhibition of ribonucleotide reductase? 
Cell-free in vitro studies have provided evidence that resveratrol is an inhibitor 
of DNA polymerase α and δ (Stivala et al., 2001) and of ribonucleotide 
reductase (Fontecave et al., 1998). Additionally, experiments performed in a 
fibroblast cell line revealed that the ribonucleotide reductase inhibitor 
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hydroxyurea also leads to accumulation of cells in early S-phase that is 
accompanied by an increase in hyperphosphorylated Rb (Linke et al., 1996). So 
far, two distinct studies point to similarities between resveratrol and hydroxyurea 
in terms of ribonucleotide reductase inhibition (Fontecave et al., 1998; Rodrigue 
et al., 2001). Our results show, however, that resveratrol completely prevents 
further S-phase progression in cells released from aphidicolin block, suggesting 
that a preceding depletion of the deoxyribonucleotide pools is not a prerequisite 
for resveratrol-induced cell cycle arrest in VSMCs.  
Taken together, resveratrol seems to block DNA replication in VSMCs similar to 
the DNA polymerase inhibitor aphidicolin. 
2.5 Influence on p53 phosphorylation, expression and transactivation 
The tumour suppressor protein p53 is critically involved in the cell cycle control 
and seems to play a key role in VSMC proliferation after vascular injury. In this 
context, loss of p53 activity has been implicated in the pathogenesis of human 
restenosis (Speir et al., 1994), and transfer of wild-type p53 gene has been 
shown to inhibit VSMC proliferation in vivo and in vitro (Yonemitsu et al., 1998). 
In normally proliferating cells, p53 is maintained at low levels. This is a 
consequence of its interaction with the Mdm2 protein, which targets p53 for 
ubiquitination and degradation. Stress signals such as γ-irradiation trigger p53 
phosphorylation at a number of N-terminal sites, thereby affecting its affinity for 
Mdm2 and leading to p53 stabilisation (Oren, 1999). Phosphorylation at 
serine15, in particular, has been implicated in this process (Oren, 1999; Shieh et 
al., 1997).  
However, more recent data suggest that serine15 phosphorylation does not alter 
p53 interaction with Mdm2. Instead, it is proposed to be responsible for p53 
transactivation by promoting interaction with CREB binding protein (CBP)/p300 
(Dumaz and Meek, 1999; Lambert et al., 1998; Schon et al., 2002). This seems 
to be true for VSMCs, since γ-irradiation, resveratrol and aphidicolin all cause 
enhanced serine15 phosphorylation, and γ-irradiation also transactivation, but 
fail to increase total levels of p53.  
Another possible explanation for the missing upregulation of total p53 levels 
may lie in the early time point chosen for investigation; one study performed in 
VSMCs treated with x-rays shows an increase in total p53 levels after 4 days of 
treatment, and also Mayberg et al. report a delayed p53 induction after γ-
irradiation of VSMCs (Mayberg et al., 2000). 
Our results show that a reversible DNA replication block triggered by 
substances such as aphidicolin or resveratrol leads to an increase in serine15 
phosphorylation of p53. However, in striking contrast to DNA damaging events  
such as γ-irradiation, DNA replication block does not lead to enhanced levels of 
p21, a p53 regulated protein. This suggests that serine15-phosphorylated p53 
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induced by agents blocking DNA replication is transcriptionally impaired, a 
finding that is consistent with results recently reported by Gottifredi et al. 
(Gottifredi et al., 2001). Altogether, p53 serine15 phosphorylation is likely a 
consequence rather than a cause of growth inhibition, and serine15 
phosphorylated but transcriptionally impaired p53 may thus be considered a 
marker for reversible S-phase arrest. 
However, there seem to be considerable mechanistic differences  between p53 
regulation by aphidicolin in different cell lines: In RKO cells used by Gottifredi et 
al., hydroxyurea and aphidicolin were able to suppress induction of p21 by γ-
irradiation, suggesting that p53 is held in a state of active repression. This does 
not seem to be the case in VSMCs since γ-irradiation increases p21 levels 
despite the presence of aphidicolin or resveratrol, respectively. Therefore, it 
may be speculated that the molecular mechanism of action of resveratrol and 
aphidicolin is different in VSMCs compared to RKO cells: for VSMCs, active 
repression of p53 by aphidicolin and resveratrol appears less likely; instead, it 
seems probable that the impaired response to p53 after resveratrol and 
aphidicolin treatment may be due to the lack of critical modifications or cofactors 
of the p53 protein. This way, p53 can be considered as partially latent, with the 
full transcriptional activity being restored after γ-irradiation, a stimulus known to 
entirely activate the protein.  
In summary, resveratrol and aphidicolin show very similar patterns regarding 
p53 modification alone as well as in combination with γ-irradiation. Hence, these 
results support the hypothesis that resveratrol induces a reversible S-phase 
arrest, with features very similar to the DNA polymerase inhibitor aphidicolin. 
The impact of vascular proliferative diseases such as restenosis on morbitity 
and mortality in the developed countries explains the need to find new drugs 
that may help to reduce or prevent cardiovascular complications (Garas et al., 
2001; Dzau et al., 2002). In this regard, insights into the mechanisms of action 
of a specific substance are indispensable for evaluation of its therapeutic 
potential. Resveratrol, based on data obtained in in vitro studies and animal 
experiments, has been suggested to be a potentially promising candidate (Wu 
et al., 2001). This work provides insight into the signalling pathways that are 
modulated by resveratrol in VSMCs and may thus allow a better estimation of 
its therapeutic usability, although in vivo studies are certainly needed to permit a 
final appraisal. 
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F. Summary 
The present work was intended to elucidate the molecular targets of resveratrol 
in Ang II- and calf serum-stimulated primary rat aortic VSMCs.  
1 Effect of resveratrol on Ang II-stimulated VSMCs 
Ang II is critically involved not only in modulating vasomotor tone but also in 
controlling functional and structural properties of the arterial wall.  
Our results show that resveratrol reduces VSMC hypertrophy induced by Ang II, 
and that this effect is most likely caused by an interference with Akt- and, 
although to a lesser extent, Erk 1/2-governed pathways. Additional experiments 
revealed that resveratrol-mediated attenuation of Akt phosphorylation is not due 
to activation of the respective Akt-phosphatase but is rather based on inhibition 
of pathways upstream of Akt activation. 
In this regard, our results provide evidence that c-Src kinase is not inhibited by 
resveratrol in these cells. Importantly, we were able to demonstrate that EGF-R 
transactivation, a very early event in Ang II signalling, is not affected by 
resveratrol. Consistently, Akt phosphorylation induced by EGF itself is also 
inhibited by resveratrol. On the other hand, Ang II-induced PI3-k tyrosine 
phosphorylation is substantially reduced by resveratrol pre-treatment, 
suggesting the molecular target of resveratrol to be located downstream of 
EGF-R but upstream of PI3k.  
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Fig. 42. Interference of resveratrol with pathways leading to Ang II-induced hypertrophy in 
VSMCs. Since the exact target of resveratrol is not yet identified, inhibition of the most upstream 
target in the signalling cascade is depicted.  
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2 Effect of resveratrol on calf serum-stimulated VSMCs 
VSMC proliferation is considered a pivotal step in the genesis of cardiovascular 
diseases such as atherosclerosis and restenosis after angioplasty. 
Antiproliferative effects have been previously described for resveratrol, but 
seem to vary considerably depending on the cell type investigated.  
We show that resveratrol reversibly inhibits cell cycle progression in early 
S-phase in calf serum-treated VSMCs. This effect is accompanied by an 
increase in hyperphosphorylated Rb while levels of the cdk-inhibitors p21Cip1 
and p27Kip1 are reduced compared to non treated control cells (see Fig. 43).  
Furthermore, we were able to demonstrate that resveratrol-treatment of VSMCs 
leads to an increase in serine15-phosphorylated p53 protein that is, however, 
transcriptionally impaired, since levels of p21 and Bax, two p53-regulated 
proteins, do not augment. Transcriptional impairment is likely caused by the 
lack of cofactors or critical modifications of the p53 protein, as additional 
application of γ-irradiation fully restores its transcriptional activity.  
In summary, our results provide new insight into the molecular pathways 
influenced by resveratrol in VSMCs, and may help to better evaluate the 
potential of this substance as a possible therapeutic agent in cardiovascular 
disease.  
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Fig. 43. Inhibition of cell cycle progression by resveratrol in calf serum-stimulated VSMCs. While 
signalling in G1-phase seems not to be affected, resveratrol (RV) treatment leads to a reversible 
cell cycle arrest in early S-phase. 
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G. Appendix 
1 Abbreviations 
7-AAD 7-amino-actinomycin D 
ACE angiotensin-converting enzyme 
AG AG 1478 
Ang II  angiotensin II 
AP-1 Activating protein 1 
APS ammonium persulfate 
Aph aphidicolin 
AT1/2-R angiotensin II type 1/2 receptor 
bFGF basic fibroblast growth factor 
BrdU bromodeoxyuridine 
BSA bovine serum albumine 
C Celsius 
CBP CREB binding protein 
cdk cyclin-dependent kinase 
Co control 
CREB cAMP-response-element binding protein 
CS calf serum 
DNA deoxyribonucleic acid 
DAG diacylglycerol 
DMEM Dulbecco`s Modified Eagle`s medium 
ECM extracellular matrix 
EDTA ethylene diamine tetraacetic acid 
EGF epidermal growth factor 
EGF-R epidermal growth factor receptor 
eIF2B eukaryotic initiation factor 2B 
Erk 1/2 extracellular-signal regulated kinase 1/2 
FOXO FOXO family of Forkhead transcription factors 
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GPCR G-protein coupled receptor 
Grb 2 growth factor receptor bound protein 2 
Gab 1 Grb 2-associated binder 1 
GSK 3 glycogen synthase kinase 3 
Gy Gray 
h hour 
HB heparin-binding 
IL 6 interleukin 6 
IP3 inositol trisphosphate 
IR γ-irradiation 
JNK c-Jun N-terminal kinase 
LDH lactate dehydrogenase 
LDL low density lipoprotein 
MAPK mitogen activated protein kinase 
MCP-1 monocyte chemoattractant protein 1 
m milli 
M molar 
Mdm2 mouse double minute 2 
min minutes 
MKK (MEK) MAPK kinase 
MKKK MAPK kinase kinase 
mTor mammalian target of rapamycin 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-  
  tetrazolium  bromide 
mRNA messenger RNA 
n nano 
NAC N-Acetyl-L-Cysteine 
NAD(P)H nicotinamide adenine dinucleotide (phosphate) 
NFκB nuclear factor κB 
NO nitric oxide 
NOS nitric oxide synthase 
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O.A. ocadaic acid 
p phospho 
PAA polyacrylamide 
PBS phosphate-buffered saline 
PCNA proliferating cell nuclear antigen 
PDK 1 3-phosphoinositide-dependent kinase I 
PH pleckstrin homology 
PI propidium iodide 
PI3-k phosphoinositide-3 kinase 
PKA/B/C/G protein kinase A/B/C/G 
PLC phospholipase C 
PMSF Phenylmethylsulfonyl fluoride 
PP2A protein phosphatase 2A 
PtdIns phosphatidylinsositol 
PTEN phosphatase and tensin homologue deleted from  
chromosome 10 
oxLDL oxidised LDL 
PDGF platelet-derived growth factor 
PYK 2 proline rich tyrosine kinase 2 
R restriction point 
Rb Retinoblastoma protein 
RNA ribonucleic acid 
ROS reactive oxygen species 
RV resveratrol 
S serine 
SDS sodium dodecyl sulfate 
SH1/2 Src homology 1/2 
Shc Src-homology 2 domain containing 
SHIP Src-homology 2-containing phosphatase 
Sos son of sevenless 
T threonine 
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TEMED N,N,N´,N´-tetramethylethylenediamine 
TGF-β transforming growth factor β 
TOP tract of oligopyrimidines 
TRIS Tris(hydroxymethyl)-aminomethane 
v volume 
VSMC vascular smooth muscle cell 
w weight 
WM wortmannin 
Y tyrosine 
µ micro 
2 Alphabetical order of companies 
Acros Organics Schwerte, Germany 
Amersham Pharmacia Freiburg, Germany 
Beckman Instruments Munich, Germany 
BD biosciences Heidelberg, Germany 
Biochrom Berlin, Germany 
BioRad Laboratories Munich, Germany 
BioSource Nivelle, Belgium 
Calbiochem Schwalbach, Germany 
Charles River GmbH Sulzfeld, Germany 
Cell Signaling Frankfurt, Germany 
Eppendorf Maintal, Germany 
Invitrogen Karlsruhe, Germany 
Jackson ImmunoResearch West Grove, USA 
Millipore Eschborn, Germany 
NEN Cologne, Germany 
Pan Biotech Aidenbach, Germany 
Qbiogene-Alexis Grünberg, Germany 
Peske Aindling-Pichl, Germany 
Roche Mannheim, Germany 
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Roth Karlsruhe, Germany 
Serotec Eching, Germany 
Sigma Taufkirchen, Germany 
Tocris Ellisville, USA 
Upstate Biotechnology Lake Placid, USA 
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